CA2497268A1 - Buccal, polar and non-polar spray or capsule containing drugs for treating pain - Google Patents
Buccal, polar and non-polar spray or capsule containing drugs for treating pain Download PDFInfo
- Publication number
- CA2497268A1 CA2497268A1 CA002497268A CA2497268A CA2497268A1 CA 2497268 A1 CA2497268 A1 CA 2497268A1 CA 002497268 A CA002497268 A CA 002497268A CA 2497268 A CA2497268 A CA 2497268A CA 2497268 A1 CA2497268 A1 CA 2497268A1
- Authority
- CA
- Canada
- Prior art keywords
- composition
- amount
- active compound
- percent
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
Buccal aerosol sprays or capsules using polar and non-polar solvent have now been developed which provide biologically active compounds for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, active compound, and optional flavoring agent; formulation II:
aqueous polar solvent, active compound, optionally flavoring agent, and propellant; formulation III: non-polar solvent, active compound, and optional flavoring agent; and formulation IV: non-polar solvent, active compound, optional flavoring agent, and propellant.
aqueous polar solvent, active compound, optionally flavoring agent, and propellant; formulation III: non-polar solvent, active compound, and optional flavoring agent; and formulation IV: non-polar solvent, active compound, optional flavoring agent, and propellant.
Description
BUCCAL, POLAR AND NON-POLAR SPRAY OR CAPSULE CONTAINING
DRUGS FOR TREATING PAIN
CROSS REFERENCE TO RELATED APPLICATIONS
This application is a continuation-in-part of application no. 091537,118, filed March 29, 2000 which is a continuation-in-part of the U.S. national phase designation of PCT/LTS97117899 filed October 1, 1997, the disclosures of which are incorporated by reference herein in their entirety.
BACKGROUND OF THE INVENTION
It is known that certain biologically active compounds are better absorbed through the oral mucosa than through other routes of administration, such as through the stomach or intestine. However, formulations suitable for such administration by these latter routes present their own problems. For example, the biologically active compound must be compatible with the other components of the composition such as propellants, solvents, etc.
Many such formulations have been proposed. For example, U.S.P. 4,689,233, Dvorsky et al., describes a soft gelatin capsule for the administration of the anti-coronary drug nifedipine dissolved in a mixture of polyether alcohols. U.S.P. 4,755,389, Jones et al., describes a hard gelatin chewable capsule containing nifedipine. A chewable gelatin capsule containing a solution or dispersion of a drug is described in U.S.P.
4,935,243, Borkan et al. U.S.P. 4,919,919, Aouda et al, and U.S.P. 5,370,862, Klokkers-Bethke, describe a nitroglycerin spray for administration to the oral mucosa comprising nitroglycerin, ethanol, and other components. An orally administered pump spray is described by Cholcha in U.S.P. 5,186,925. Aerosol compositions containing a hydrocarbon propellant and a drug for administration to a mucosal surface are described in U.K.
DRUGS FOR TREATING PAIN
CROSS REFERENCE TO RELATED APPLICATIONS
This application is a continuation-in-part of application no. 091537,118, filed March 29, 2000 which is a continuation-in-part of the U.S. national phase designation of PCT/LTS97117899 filed October 1, 1997, the disclosures of which are incorporated by reference herein in their entirety.
BACKGROUND OF THE INVENTION
It is known that certain biologically active compounds are better absorbed through the oral mucosa than through other routes of administration, such as through the stomach or intestine. However, formulations suitable for such administration by these latter routes present their own problems. For example, the biologically active compound must be compatible with the other components of the composition such as propellants, solvents, etc.
Many such formulations have been proposed. For example, U.S.P. 4,689,233, Dvorsky et al., describes a soft gelatin capsule for the administration of the anti-coronary drug nifedipine dissolved in a mixture of polyether alcohols. U.S.P. 4,755,389, Jones et al., describes a hard gelatin chewable capsule containing nifedipine. A chewable gelatin capsule containing a solution or dispersion of a drug is described in U.S.P.
4,935,243, Borkan et al. U.S.P. 4,919,919, Aouda et al, and U.S.P. 5,370,862, Klokkers-Bethke, describe a nitroglycerin spray for administration to the oral mucosa comprising nitroglycerin, ethanol, and other components. An orally administered pump spray is described by Cholcha in U.S.P. 5,186,925. Aerosol compositions containing a hydrocarbon propellant and a drug for administration to a mucosal surface are described in U.K.
2,082,457, Su, U.S.P. 3,155,574, Silson et al., U.S.P. 5,011,678, Wang et al., and by Parnell in U.S.P. 5,128,132. It should be noted that these references discuss bioavailability of solutions by inhalation rather than through the membranes to which they are administered.
ST.JMMARY OF THE INVENTION
A buccal aerosol spray or soft bite gelatin capsule using a polar or non-polar solvent has now been developed which provides biologically active compounds for rapid absorption through the oral mucosa, resulting in fast onset of effect.
The buccal aerosol spray compositions of the present invention, for transmucosal administration of a pharmacologically active compound soluble in a pharmacologically acceptable non-polar solvent comprise in weight % of total composition:
pharmaceutically acceptable propellant 5-80 %, nonpolar solvent 19-85 %, active compound 0.05-50 %, suitably additionally comprising, by weight of total composition a flavoring agent 0.01-10 %. Preferably the composition comprises: propellant 10-70 %, non-polar solvent 25-89.9 %, active compound 0.01-40 %, flavoring agent 1-8 %; most suitably propellant 20-70 %, non-polar solvent 25-74.75 %, active compound 0.25-35 %, flavoring agent 2-7.5 %.
The buccal polar aerosol spray compositions of the present invention, for transmucosal administration of a pharmacologically active compound soluble in a pharmacologically acceptable polar solvent axe also administrable in aerosol form driven by a propellant. In this case, the composition comprises in weight % of total composition:
aqueous polar solvent 10-97 %, active compound 0.1-25 %, suitably additionally comprising, by weight of total composition a flavoring agent 0.05-10 % and propellant: 2 -10 %. Preferably the composition comprises: polar solvent 20-97 %, active compound 0.1-15%, flavoring agent 0.1-5 % and propellant 2-5 %; most suitably polar solvent 25-97 %, active compound 0.2-25 %, flavoring agent 0.1-2.5 % and propellant 2-4 %.
The buccal pump spray composition of the present invention, i.e., the propellant free composition, for transmucosal administration of a pharmacologically active compound wherein said active compound is soluble in a pharmacologically acceptable non-polar solvent comprises in weight % of total composition: non-polar solvent 30-99.69 %, active compound 0.005-55 %, and suitably additionally, flavoring agent 0.1-10 %.
The buccal polar pump spray compositions of the present invention, i.e., the propellant free composition, for transmucosal administration of a pharmacologically active compound soluble in a pharmacologically acceptable polar solvent comprises in weight of total composition: aqueous polar solvent 30-99.69 %, active compound 0.001-60 %, suitably additionally comprising, by weight of total composition a flavoring agent 0.1-10 %.
Preferably the composition comprises: polar solvent 37-98.58 %, active compound 0.005-55 %, flavoring agent 0.5-8 %; most suitably polar solvent 60.9-97.06 %, active compound 0.01-40 %, flavoring agent 0.75-7.5 %.
The soft bite gelatin capsules of the present invention for transmucosal administration of a pharmacologically active compound, at least partially soluble in a pharmacologically acceptable non-polar solvent, having charged thereto a fill composition comprise in weight % of total composition: non-polar solvent 4-99.99 %, emulsifier 0-20 %, active compound 0.01-80 %, provided that said fill composition contains less than 10 % of water, suitably additionally comprising, by weight of the composition:
flavoring agent 0.01-10 %. Preferably, the soft bite gelatin capsule comprises: non-polar solvent 21.5-99.975 %, emulsifier 0-15 %, active compound 0.025-70 %, flavoring agent 1-8 %; most suitably:
nonpolar solvent 28.5-97.9 %, emulsifier 0-10 %, active compound 0.1-65.0 %, flavoring agent 2-6 %.
The soft bite polar gelatin capsules of the present invention for transmucosal administration of a pharmacologically active compound, at least partially soluble in a pharmacologically acceptable polar solvent, having charged thereto a composition comprising in weight % of total composition: polar solvent 25-99.89 %, emulsifier 0-20 %, active compound 0.01-65 %, provided that said composition contains less than 10 % of water, suitably additionally comprising, by weight of the composition:
flavoring agent O1-10 %. Preferably, the soft bite gelatin capsule comprises: polar solvent 37-99.95 %, emulsifier 0-15 %, active compound 0.025-55 %, flavoring agent 1-8 %; most suitably:
polar solvent 44-96.925 %, emulsifier 0-10 %, active compound 0.075-50 %, flavoring agent 2-6 %.
It is an object of the invention to coat the mucosal membranes either with extremely fine droplets of spray containing the active compounds or a solution or paste thereof from bite capsules.
It is also an object of the invention to administer to the oral mucosa of a mammalian in need of same, preferably man, by spray or bite capsule, a predetermined amount of a biologically active compound by this method or from a soft gelatin capsule.
A further object is a sealed aerosol spray container containing a composition of the non polar or polar aerosol spray formulation, and a metered valve suitable for releasing from said container a predetermined amount of said composition.
As the propellant evaporates after activation of the aerosol valve, a mist of fme droplets is formed which contains solvent and active compound.
The propellant is a non-Freon material, preferably a C3_8 hydrocarbon of a linear or branched configuration. The propellant should be substantially non-aqueous. The propellant produces a pressure in the aerosol container such that under expected normal usage it will produce sufficient pressure to expel the solvent from the container when the valve is activated but not excessive pressure such as to damage the container or valve seals.
ST.JMMARY OF THE INVENTION
A buccal aerosol spray or soft bite gelatin capsule using a polar or non-polar solvent has now been developed which provides biologically active compounds for rapid absorption through the oral mucosa, resulting in fast onset of effect.
The buccal aerosol spray compositions of the present invention, for transmucosal administration of a pharmacologically active compound soluble in a pharmacologically acceptable non-polar solvent comprise in weight % of total composition:
pharmaceutically acceptable propellant 5-80 %, nonpolar solvent 19-85 %, active compound 0.05-50 %, suitably additionally comprising, by weight of total composition a flavoring agent 0.01-10 %. Preferably the composition comprises: propellant 10-70 %, non-polar solvent 25-89.9 %, active compound 0.01-40 %, flavoring agent 1-8 %; most suitably propellant 20-70 %, non-polar solvent 25-74.75 %, active compound 0.25-35 %, flavoring agent 2-7.5 %.
The buccal polar aerosol spray compositions of the present invention, for transmucosal administration of a pharmacologically active compound soluble in a pharmacologically acceptable polar solvent axe also administrable in aerosol form driven by a propellant. In this case, the composition comprises in weight % of total composition:
aqueous polar solvent 10-97 %, active compound 0.1-25 %, suitably additionally comprising, by weight of total composition a flavoring agent 0.05-10 % and propellant: 2 -10 %. Preferably the composition comprises: polar solvent 20-97 %, active compound 0.1-15%, flavoring agent 0.1-5 % and propellant 2-5 %; most suitably polar solvent 25-97 %, active compound 0.2-25 %, flavoring agent 0.1-2.5 % and propellant 2-4 %.
The buccal pump spray composition of the present invention, i.e., the propellant free composition, for transmucosal administration of a pharmacologically active compound wherein said active compound is soluble in a pharmacologically acceptable non-polar solvent comprises in weight % of total composition: non-polar solvent 30-99.69 %, active compound 0.005-55 %, and suitably additionally, flavoring agent 0.1-10 %.
The buccal polar pump spray compositions of the present invention, i.e., the propellant free composition, for transmucosal administration of a pharmacologically active compound soluble in a pharmacologically acceptable polar solvent comprises in weight of total composition: aqueous polar solvent 30-99.69 %, active compound 0.001-60 %, suitably additionally comprising, by weight of total composition a flavoring agent 0.1-10 %.
Preferably the composition comprises: polar solvent 37-98.58 %, active compound 0.005-55 %, flavoring agent 0.5-8 %; most suitably polar solvent 60.9-97.06 %, active compound 0.01-40 %, flavoring agent 0.75-7.5 %.
The soft bite gelatin capsules of the present invention for transmucosal administration of a pharmacologically active compound, at least partially soluble in a pharmacologically acceptable non-polar solvent, having charged thereto a fill composition comprise in weight % of total composition: non-polar solvent 4-99.99 %, emulsifier 0-20 %, active compound 0.01-80 %, provided that said fill composition contains less than 10 % of water, suitably additionally comprising, by weight of the composition:
flavoring agent 0.01-10 %. Preferably, the soft bite gelatin capsule comprises: non-polar solvent 21.5-99.975 %, emulsifier 0-15 %, active compound 0.025-70 %, flavoring agent 1-8 %; most suitably:
nonpolar solvent 28.5-97.9 %, emulsifier 0-10 %, active compound 0.1-65.0 %, flavoring agent 2-6 %.
The soft bite polar gelatin capsules of the present invention for transmucosal administration of a pharmacologically active compound, at least partially soluble in a pharmacologically acceptable polar solvent, having charged thereto a composition comprising in weight % of total composition: polar solvent 25-99.89 %, emulsifier 0-20 %, active compound 0.01-65 %, provided that said composition contains less than 10 % of water, suitably additionally comprising, by weight of the composition:
flavoring agent O1-10 %. Preferably, the soft bite gelatin capsule comprises: polar solvent 37-99.95 %, emulsifier 0-15 %, active compound 0.025-55 %, flavoring agent 1-8 %; most suitably:
polar solvent 44-96.925 %, emulsifier 0-10 %, active compound 0.075-50 %, flavoring agent 2-6 %.
It is an object of the invention to coat the mucosal membranes either with extremely fine droplets of spray containing the active compounds or a solution or paste thereof from bite capsules.
It is also an object of the invention to administer to the oral mucosa of a mammalian in need of same, preferably man, by spray or bite capsule, a predetermined amount of a biologically active compound by this method or from a soft gelatin capsule.
A further object is a sealed aerosol spray container containing a composition of the non polar or polar aerosol spray formulation, and a metered valve suitable for releasing from said container a predetermined amount of said composition.
As the propellant evaporates after activation of the aerosol valve, a mist of fme droplets is formed which contains solvent and active compound.
The propellant is a non-Freon material, preferably a C3_8 hydrocarbon of a linear or branched configuration. The propellant should be substantially non-aqueous. The propellant produces a pressure in the aerosol container such that under expected normal usage it will produce sufficient pressure to expel the solvent from the container when the valve is activated but not excessive pressure such as to damage the container or valve seals.
The non-polar solvent is a non-polar hydrocarbon, preferably a C7_is hydrocarbon of a linear or branched configuration, fatty acid esters, and triglycerides, such as miglyol. The solvent must dissolve the active compound and be miscible with the propellant, i.e., solvent and propellant must form a single phase at a temperature of 0-40°C
a pressure range of between 1-3 atm.
The polar and non-polar aerosol spray compositions of the invention are intended to be administered from a sealed, pressurized container. Unlike a pump spray, which allows the entry of air into the container after every activation, the aerosol container of the invention is sealed at the time of manufacture. The contents of the container are released by activation of a metered valve, which does not allow entry of atmospheric gasses with each activation. Such containers are commercially available.
A further object is a pump spray container containing a composition of the pump spray formulation, and a metered valve suitable for releasing from said container a predetermined amount of said composition.
A further object is a soft gelatin bite capsule containing a composition of as set forth above. The formulation may be in the form of a viscous solution or paste containing the active compounds. Although solutions are preferred, paste fills may also be used where the active compound is not soluble or only partially soluble in the solvent of choice. Where water is used to form part of the paste composition, it should not exceed 10 % thereof. (All percentages herein are by weight unless otherwise indicated.) The polar or non-polar solvent is chosen such that it is compatible with the gelatin~shell and the active compound. The solvent preferably dissolves the active compound. However, other components wherein the active compound is not soluble or only slightly soluble may be used and will form a paste fill.
Soft gelatin capsules are well known in the art. See, for example, U.S.P.
a pressure range of between 1-3 atm.
The polar and non-polar aerosol spray compositions of the invention are intended to be administered from a sealed, pressurized container. Unlike a pump spray, which allows the entry of air into the container after every activation, the aerosol container of the invention is sealed at the time of manufacture. The contents of the container are released by activation of a metered valve, which does not allow entry of atmospheric gasses with each activation. Such containers are commercially available.
A further object is a pump spray container containing a composition of the pump spray formulation, and a metered valve suitable for releasing from said container a predetermined amount of said composition.
A further object is a soft gelatin bite capsule containing a composition of as set forth above. The formulation may be in the form of a viscous solution or paste containing the active compounds. Although solutions are preferred, paste fills may also be used where the active compound is not soluble or only partially soluble in the solvent of choice. Where water is used to form part of the paste composition, it should not exceed 10 % thereof. (All percentages herein are by weight unless otherwise indicated.) The polar or non-polar solvent is chosen such that it is compatible with the gelatin~shell and the active compound. The solvent preferably dissolves the active compound. However, other components wherein the active compound is not soluble or only slightly soluble may be used and will form a paste fill.
Soft gelatin capsules are well known in the art. See, for example, U.S.P.
4,935,243, Borkan et al., for its teaching of such capsules. The capsules of the present invention are intended to be bitten into to release the low viscosity solution or paste therein, which will then coat the buccal mucosa with the active compounds. Typical capsules, which are swallowed whole or bitten and then swallowed, deliver the active compounds to the stomach, which results in significant lag time before maximum blood levels can be achieved or subject the compound to a large first pass effect. Because of the enhanced absorption of the compounds through the oral mucosa and no chance of a first pass effect, use of the bite capsules of the invention will eliminate much of the lag time, resulting in hastened onset of biological effect. The shell of a soft gelatin capsule of the invention may comprise, for example: gelatin: 50-75 %, glycerin 20-30 %, colorants 0.5-1.5 %, water 5-10 %, and sorbitol 2-10 %.
The active compound may include, biologically active peptides, central nervous system active amines, sulfonyl areas, antibiotics, a~ztifungals, antivirals, sleep inducers, antiasthmatics, bronchial dilators, antiemetics, histamine H-2 receptor antagonists, barbiturates, prostaglandins and neutraceuticals.
The active compounds may also include antihistamines, alkaloids, hormones, benzodiazepines and narcotic analgesics. While not limited thereto, these active compounds are particularly suitable for non-polar pump spray formulation and application.
The active compounds may also include nerve impulse inhibitors, anti-opioid agents, anti-migraine agents, anti-muscle spasm agents, pain control agents, anesthetics, anti-inflammatory drugs, or mixtures thereof.
BRIEF DESCRIPTION OF THE DRAWING
FIG 1. is a schematic diagram showing routes of absorption and processing of pharmacologically active substances in a mammalian system.
DESCRIPTION OF THE PREFERRED EMBODIMENTS
The preferred active compounds of the present invention are in an ionized, salt form or as the free base of the pharmaceutically acceptable salts thereof (provided, for the aerosol or pump spray compositions, they are soluble in the spray solvent). These compounds are soluble in the non-polar solvents of the invention at useful concentrations or can be prepared as pastes at useful concentrations. These concentrations may be less than the standard accepted dose for these compounds since there is enhanced absorption of the compounds through the oral mucosa. This aspect of the invention is especially important when there is a large (40-99.99%) first pass effect.
As propellants for the non polar sprays, propane, N-butane, iso-butane, N-pentane, iso-pentane, and neo-pentane, and mixtures thereof may be used. N-butane and iso-butane, as single gases, are the preferred propellants. It is permissible for the propellant to have a water content of no more than 0.2%, typically 0.1-0.2%. All percentages herein are by weight unless otherwise indicated. It is also preferable that the propellant be synthetically produced to minimize the presence of contaminants which are harmful to the active compounds. These contaminants include oxidizing agents, reducing agents, Lewis acids or bases, and water. The concentration of each of these should be less than 0.1 %, except that water may be as high as 0.2%.
Suitable non-polar solvents for the capsules and the non-polar sprays include (CZ C24) fatty acid (Cz C6) esters, C~ Cl8 hydrocarbon, Ci C6 alkanoyl esters, and the triglycerides of the corresponding acids. When the capsule fill is a paste, other liquid components may be used instead of the above low molecular weight solvents.
These include soya oil, corn oil, other vegetable oils.
As solvents for the polar capsules or sprays there may be used low molecular weight polyethyleneglycols (PEG) of 400-1000 Mw (preferably 400-600), low molecular weight (CZ C$) mono and polyols and alcohols of C~ C1$ linear or branch chain hydrocarbons, glycerin may also be present and water may also be used in the sprays, but only in limited amount in the capsules.
It is expected that some glycerin and water used to make the gelatin shell will migrate from the shell to the fill during the curing of the shell. Likewise, there may be some migration of components from the fill to the shell during curing and even throughout the shelf life of the capsule.
Therefore, the values given herein are for the compositions as prepared, it being within the scope of the invention that minor variations will occur.
The preferred flavoring agents are synthetic or natural oil of peppermint, oil of spearmint, citrus oil, fruit flavors, sweeteners (sugars, aspartame, saccharin, etc.), and combinations thereof.
The active substances include the active compounds selected from the group consisting of cyclosporine, sermorelin, octreotide acetate, calcitonin-salmon, insulin lispro, sumatriptan succinate, clozepine, cyclobenzaprine, dexfenfluramine hydrochloride, glyburide, zidovudine, erythromycin, ciprofloxacin, ondansetron hydrochloride, dimenhydrinate, cimetidine hydrochloride, famotidine, phenytoin sodium, phenytoin, carboprost thromethamine, carboprost, diphenhydramine hydrochloride, isoproterenol hydrochloride, terbutaline sulfate, terbutaline, theophylline, albuterol sulfate and neutraceuticals, that is to say nutrients with pharmacological action such as but not limited to carnitine, valerian, echinacea, and the like.
The active compound may include, biologically active peptides, central nervous system active amines, sulfonyl areas, antibiotics, a~ztifungals, antivirals, sleep inducers, antiasthmatics, bronchial dilators, antiemetics, histamine H-2 receptor antagonists, barbiturates, prostaglandins and neutraceuticals.
The active compounds may also include antihistamines, alkaloids, hormones, benzodiazepines and narcotic analgesics. While not limited thereto, these active compounds are particularly suitable for non-polar pump spray formulation and application.
The active compounds may also include nerve impulse inhibitors, anti-opioid agents, anti-migraine agents, anti-muscle spasm agents, pain control agents, anesthetics, anti-inflammatory drugs, or mixtures thereof.
BRIEF DESCRIPTION OF THE DRAWING
FIG 1. is a schematic diagram showing routes of absorption and processing of pharmacologically active substances in a mammalian system.
DESCRIPTION OF THE PREFERRED EMBODIMENTS
The preferred active compounds of the present invention are in an ionized, salt form or as the free base of the pharmaceutically acceptable salts thereof (provided, for the aerosol or pump spray compositions, they are soluble in the spray solvent). These compounds are soluble in the non-polar solvents of the invention at useful concentrations or can be prepared as pastes at useful concentrations. These concentrations may be less than the standard accepted dose for these compounds since there is enhanced absorption of the compounds through the oral mucosa. This aspect of the invention is especially important when there is a large (40-99.99%) first pass effect.
As propellants for the non polar sprays, propane, N-butane, iso-butane, N-pentane, iso-pentane, and neo-pentane, and mixtures thereof may be used. N-butane and iso-butane, as single gases, are the preferred propellants. It is permissible for the propellant to have a water content of no more than 0.2%, typically 0.1-0.2%. All percentages herein are by weight unless otherwise indicated. It is also preferable that the propellant be synthetically produced to minimize the presence of contaminants which are harmful to the active compounds. These contaminants include oxidizing agents, reducing agents, Lewis acids or bases, and water. The concentration of each of these should be less than 0.1 %, except that water may be as high as 0.2%.
Suitable non-polar solvents for the capsules and the non-polar sprays include (CZ C24) fatty acid (Cz C6) esters, C~ Cl8 hydrocarbon, Ci C6 alkanoyl esters, and the triglycerides of the corresponding acids. When the capsule fill is a paste, other liquid components may be used instead of the above low molecular weight solvents.
These include soya oil, corn oil, other vegetable oils.
As solvents for the polar capsules or sprays there may be used low molecular weight polyethyleneglycols (PEG) of 400-1000 Mw (preferably 400-600), low molecular weight (CZ C$) mono and polyols and alcohols of C~ C1$ linear or branch chain hydrocarbons, glycerin may also be present and water may also be used in the sprays, but only in limited amount in the capsules.
It is expected that some glycerin and water used to make the gelatin shell will migrate from the shell to the fill during the curing of the shell. Likewise, there may be some migration of components from the fill to the shell during curing and even throughout the shelf life of the capsule.
Therefore, the values given herein are for the compositions as prepared, it being within the scope of the invention that minor variations will occur.
The preferred flavoring agents are synthetic or natural oil of peppermint, oil of spearmint, citrus oil, fruit flavors, sweeteners (sugars, aspartame, saccharin, etc.), and combinations thereof.
The active substances include the active compounds selected from the group consisting of cyclosporine, sermorelin, octreotide acetate, calcitonin-salmon, insulin lispro, sumatriptan succinate, clozepine, cyclobenzaprine, dexfenfluramine hydrochloride, glyburide, zidovudine, erythromycin, ciprofloxacin, ondansetron hydrochloride, dimenhydrinate, cimetidine hydrochloride, famotidine, phenytoin sodium, phenytoin, carboprost thromethamine, carboprost, diphenhydramine hydrochloride, isoproterenol hydrochloride, terbutaline sulfate, terbutaline, theophylline, albuterol sulfate and neutraceuticals, that is to say nutrients with pharmacological action such as but not limited to carnitine, valerian, echinacea, and the like.
In another embodiment, the active compound is a nerve impulse inhibitor, anti-opioid agent, anti-migraine agent, anti-muscle spasm agent, pain control agent, anesthetic, anti-inflammatory drug, or a mixture thereof.
In one embodiment the active compound is a nerve impulse inhibitor.
Suitable nerve impulse inhibitors for use in the buccal sprays of the invention include, but are not limited to levobupivacaine, lidocaine, prilocaine, mepivacaine, propofol, rapacuronium bromide, ropivacaine, tubocurarine, atracurium, doxacurium, mivacurium, pancuronium, vecuronium, pipecuronium, rocuronium, and mixtures thereof.
In one embodiment the active compound is an anti-opioid agent. Suitable anti-opioid agents for use in the buccal sprays of the invention include, but are not limited to, naloxone, nalinefene, naltrexone, cholecystokinin, nociceptin, neuropeptide FF, oxytocin, vasopressin, and mixtures thereof.
In one embodiment the active compound is an anti-migraine agent. Suitable anti-migraine agents for use in the buccal sprays of the invention include, but axe not limited to, frovatriptan, zolmitriptan, rizatriptan, almotriptan, eletriptan, naratriptan, alinotriptan, ergotamine, diethylergotamine, sumatriptan, and mixtures thereof.
In one embodiment the active compound is an anti-muscle spasm agent.
Suitable anti-muscle spasm agents for use in the buccal sprays of the invention include, but are not limited to, baclofen, botulinum toxin, carisoprodol, chlorphenesin, chlorzoxazone, cyclobenzaprine, dantrolene, diazepam, metaxalone, methocarbamol, orphenadrine, tizanidine, and mixtures thereof.
In one embodiment the active compound is a pain control agent. Suitable pain control agents for use in the buccal sprays of the invention include, but are not limited to, non-steroidal anti-inflammatory drugs, alfentanil, butorphanol, codeine, dezocine, fentanyl, hydrocodone, hydromorphone, levorphanol, meperidine, methadone, morphine, nalbuphine, oxycodone, oxymorphone, propoxyphene, pentazocine, sufentanil, tramadol, and mixtures thereof.
In one embodiment the active compound is an anesthetic. Suitable anesthetics for use in the buccal sprays of the invention include, but axe not limited to, benzonatate, bupivacaine, desflurane, enflurane, isoflurane, levobupivacaine, lidocaine, mepivacaine, prilocaine, propofol, rapacuronium bromide, ropivacaine, sevoflurane, ltetamine, and mixtures thereof.
7_ In one embodiment the active compound is an anti-inflammatory drug.
Suitable anti-inflammatory drugs for use in the buccal sprays of the invention include, but are not limited to, alosetron, anakinra, beclomethasone, betamethasone, budesonide, clobetasol, celecoxib, cromolyn, desoximetasone, dexamethasone, epinastic, etanercept, etoricoxib, flunisolide, fluocinonide, fluticasone, formoterol, hydrocortisone, hydroxychloroquine, ibudilast, ketotifen, meloxicam, mesalamine, methotrexate, methylprednisolone, mometasone, montelukast, nedocromil, olsala.zine, prednisone, ramatroban, rofecoxib, salsalate, terbutaline, triamcinolone, valdecoxib, zafirlukast, and mixtures thereof.
The formulations of the present invention comprise an active compound or a pharmaceutically acceptable salt thereof. The term "pharmaceutically acceptable salts"
refers to salts prepared from pharmaceutically acceptable non-toxic acids or bases including organic and inorganic acids or bases.
When an active compound of the present invention is acidic, salts may be prepared from pharmaceutically acceptable non-toxic bases. Salts derived from all stable forms of inorganic bases include aluminum, ammonium, calcium, copper, iron, lithium, magnesium, manganese, potassium, sodium, zinc, etc. Particularly preferred are the ammonium, calcium, magnesium, potassium, and sodium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurnng substituted amines, cyclic amines and basic ion-exchange resins such as arginine, betaine, caffeine, choline, N,N dibenzylethylenediamine, diethylamine, 2-diethylarninoethanol, 2-dimethyl-aminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, isopropylamine, lysine, methyl-glucosamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purine, theobromine, triethylamine, trimethylamine, tripropylamine, etc.
When an active compound of the present invention is basic, salts may be prepared from pharmaceutically acceptable non-toxic acids. Such acids include acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethane-sulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, malefic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p-toluenesulfonic, etc. Particularly preferred are citric, hydrobromic, malefic, phosphoric, sulfuric, and tartaric acids.
_S_ In the discussion of methods of treatment herein, reference to the active compounds is meant to also include the pharmaceutically acceptable salts thereof. While certain formulations are set forth herein, the actual amounts to be administered to the mammal or man in need of same are to be determined by the treating physician.
The invention is further defined by reference to the following examples, which are intended to be illustrative and not limiting.
The following are examples of certain classes. All values unless otherwise specified are in weight percent.
_g_ EXAMPLES
Biologically active peptides including peptide hormones A. Cyclosp orine lingualray sp Amounts preferred amountmost preferred amount cyclosporine 5-50 10-35 15-25 water 5-20 7.5-50 9.5-12 ethanol 5-60 7.5-50 10-20 polyethylene 20-60 30-45 35-40 glycol flavors 0.1-5 1-4 2-3 B. C~p orine Non-Polar lingual spray Amounts preferred amount most preferred amount cyclosporine 1-50 3-40 5-30 Migylol 20 25 30-40 Polyoxyethylated 25 30-40 castor oil 20 Butane 25-~0 30-70 33-50 flavors 0.1-5 1-4 2-3 C. Cyclosp orine non-polar bite capsule Amounts preferred amountmost preferred amount cyclosporine 1-35 5-25 10-20 olive oil 25-60 35-55 30-45 polyoxyethylated oleic glycerides25-60 35-55 30-45 flavors 0.1-5 1-4 2-3 D. Cyclos~orine bite ca sule Amounts preferred amountmost preferred amount cyclosporine 5-50 10-35 15-25 polyethylene glycol20-60 30-45 35-40 glycerin 5-30 7.5-25 10-20 propylene glycol 5-30 7.5-25 10-20 flavors 0.1-10 1-8 3-6 E. Sermorelin (as the acetate) lin ual spray Amounts preferred amountmost preferred sermorelin (as the acetate) .O1-5 .1-3 .2-1.0 mannitol 1-25 5-20 10-15 monobasic sodium phosphate, 0.1-5 1-3 1 .5-2.5 dibasic sodium phosphate 0.01-5 .OS-3 0.1-0.5 water ethanol 5-30 7.5-25 9.5-15 polyethylene glycol 20-60 30-45 35-40 propylene glycol 5-25 10-20 12-17 flavors 0.1-5 1-4 2-3 F. Octreotide acetate (Sandostatinl pray lin ug-al ss Amounts preferred amountmost preferred amount octreotide acetate 0.001-0.50.005-0.250 0.01-0.10 acetic acid 1-10 2-8 4-6 sodium acetate 1-10 2-8 4-6 sodium chloride 3-30 .5-25 15-20 flavors 0.1-5 0.5-.4 2-3 ethanol 5-30 7.5-20 9.5-15 water 1 S-95 35-90 65-85 flavors 0.1-5 1-4 2-3 G. Calcitonin-salmon lin ug-al sal spray Amounts preferred amountmost preferred amount calcitonin-salmon 0.001-5 0.005-2 O1-1.5 ethanol 2-15 3-10 7-9.5 water 30-95 50-90 60-80 polyethylene glycol2-15 3-10 7-9.5 sodium chloride 2.5-20 5-15 10-12.5 flavors 0.1-5 1-4 2-3 H. Insulin lispro, lin~praX
Amounts preferred amountmost preferred amount insulin 20-60 4-55 5-50 glycerin 0.1-10 0.25-S 0.1-1.5 dibasic sodium phosphate1-15 2.5-10 4-8 m-cresol, 1-25 5-25 7.5-12.5 zinc oxide 0.01-0.25 .OS-0.15 0.075-0.10 m-cresol 0.1-1 0.2-0.8 0.4-0.6 phenol trace amountstrace amounts trace amounts ethanol 5-20 7.5-15 9-12 water 30-90 40-80 50-75 propylene glycol 5-20 7.5-1 S 9-12 flavors 0.1-5 0.5-3 0.75-2 adjust pH to 7.0-7.8 CI or NaOH
with H
CNS active amines their salts: including and but not limited to tricyclic amines, GABA
analogues, thiazides, agonists and serotonin phenothiazine derivatives, serotonin ant reuptake inhibitors A. Sumatrip tan succinate lin ~ual spray Amounts preferred amount most preferred amount sumatriptan succinate0.5-30 1-20 10-15 ethanol 5-60 7.5-50 10-20 propylene glycol 5-30 7.5-20 10-15 polyethylene glycol0-60 30-45 35-40 water 5-30 7.5-20 10-15 flavors 0.1-5 1-4 2-3 B. Sumatriptan succinate bite capsule Amounts preferred amountmost preferred amount sumatriptan succinate 0.01-5 0.05-3.5 0.075-1.75 polyethylene glycol 25-70 30-60 35-50 glycerin 25-70 30-60 35-50 flavors 0.1-10 1-~ 3-6 C. Clozepine lin ug-al sal spray Amounts preferred amountmost preferred amount clozepine 0.5-30 1-20 10-15 ethanol S-60 7.5-50 10-20 propylene glycol 5-30 7.5-20 10-15 polyethylene glycol 0-60 30-45 35-40 water 5-30 7.5-20 10-15 flavors 0.1-5 1-4 2-3 D. Clozepine non-polar lingual spra~with propellant Amounts preferred amountmost preferred amount clozepine 0.5-30 1-20 10-15 Migylol 20-85 25-70 30-40 Butanol 5-80 30-75 60-70 flavors 0.1-5 1-4 2-3 E. Clozepine non-polar ropellant lingual spray without p Amounts preferred amountmost preferred amount clozepine 0.5-3 0 1-20 10-1 S
Migylol 70-99.5 80-99 85-90 flavors 0.1-5 1-4 2-3 F. Cyclobenzaprine olar lin non-p ual spray _ Amounts preferred amountmost preferred amount cyclobenzaprine 1-20 10-15 (base) 0.5-30 Migylol 20-85 25-70 30-40 Iso-butane15-80 30-75 60-70 flavors 0.1-5 1-4 2-3 G. Dexfenfluramine hydrochloride lin ug-al sspray Amounts preferred amountmost preferred amount dexfenfluramine 5-30 7.5-20 10-15 Hcl ethanol 5-60 7.5-50 10-20 propylene glycol 5-30 7.5-20 10-15 polyethylene glycol 0-60 30-45 35-40 water S-30 7.5-20 10-15 flavors 0.1-5 1-4 2-3 Sulfonylureas A. Glyburide lingual spray Amounts preferred amountmost preferred amount glyburide 0.25-25 0.5-20 0.75-15 ethanol 5-60 -7.5-50 10-20 propylene glycol 5-30 7.5-20 10-15 polyethylene glycol 0-60 30-45 35-40 water 2.5-30 5-20 6-15 flavors 0.1-5 1-4 2-3 B. Glyburide non-polar bite capsule Amounts preferred amountmost preferred amount glyburide 0.01-10 0.025-7.5 0.1-4 olive oil 30-60 35-55 30-50 polyoxyethylated oleic glycerides 30-60 35-55 30-50 flavors 0.1-5 1-4 2-3 Antibiotics anti-fungals and anti-virals A. Zidovudine called azidothymidine(AZTI (Retrovir~]
[formerly non-polar lingual spray Amounts preferred amountmost preferred amount zidovudine 10-50 15-40 25-35 Soya oil 20-85 25-70 30-40 Butane 15-80 30-75 60-70 flavors 0.1-5 1-4 2-3 B. E , hromycin bite capsule bite capsule Amounts preferred amountmost preferred amount erythromycin 25-65 30-50 35-45 polyoxyethylene 5-70 30-60 45-55 glycol glycerin 5-20 7.5-15 10-12.5 flavors 1-10 2-8 3-6 C. Ciprofloxacin hydrochloride bite capsule Amoun ts preferred amount most preferred amount ciprofloxacin hydrochloride 25-6535-55 40-50 glycerin 5-20 7.5-15 10-12.5 polyethylene glycol120-75 30-65 40-60 flavors 1-10 2-8 3-6 D. zidovudine jformerly AZT)~Retrovirl] lingual called spray azidoth idine Amounts preferred amountmost preferred amount zidovudine 10-50 15-40 25-35 water 30-80 40-75 45-70 ethanol 5-20 7.5-15 9.5-12.5 polyethylene glycol5-20 7.5-15 9.5-12.5 flavors 0.1-5 1-4 2-3 Anti-emetics A. Ondansetron hydrochloride lingual spray Amounts preferred amountmost preferred amount ondansetron hydrochloride1-25 2-20 2.5-15 citric acid monohydrate 1-10 2-8 2.5-5 sodium citrate dihydrate 0.5-5 1-4 1.25-2.5 water 1-90 5-85 10-75 ethanol 5-30 7.5-20 9.5-15 propylene glycol 5-30 7.5-20 9.5-15 polyethylene glycol 5-30 7.5-20 9.5-15 flavors 1-10 3-8 5-7.5 B. Dimenh~drinate bite capsule Amountspreferred amount most preferred amount dimenhydrinate 0.5-30 2-25 3-15 glycerin 5-20 7.5-15 10-12.5 polyethylene glycol45-95 50-90 55-85 flavors 1-10 2-8 3-6 C. Dimenhydrinate olar lin ~tg<
p al spray Amountspreferred amount most preferred amount dimenhydrinate 3-50 4-40 5-35 water 5-90 10-80 15-75 ethanol 1-80 3-50 5-10 polyethylene glycol 1-80 3-50 5-15 sorbitol 0.1-5 0.2-40 0.4-1.0 aspartame 0.01-0.50.02-0.4 0.04-0.1 flavors 0.1-5 1-4 2-3 Histamine H-2 receptor antagonists A. Cimetidine hydrochloride bite capsule Amounts preferred amountmost preferred amount cimetidine HCl 10-60 15-55 25-50 glycerin 5-20 7.5-15 10-12.5 polyethylene glycol 20-90 25-85 30-75 flavors 1-10 2-8 3-6 B. Famotidine lingual spray Amounts preferred amountmost preferred amount famotidine 1-35 5-30 7-20 water 2.5-25 3-20 5-10 L-aspartic acid 0.1-20 1-15 5-10 polyethylene glycol 20-97 30-95 50-85 flavors 0.1-10 1-7.5 2-5 C. Famotidine non-polar ng-al sspray lin Amounts preferred amountmost preferred amount famotidine 1-35 5-30 7-20 Soya oil 10-50 15-40 15-20 Butanel 5-80 30-75 45-70 polyoxyethylated oleic glycerides 10-50 15-40 1 S-20 flavors 0.1-5 1-4 2-3 Barbiturates A. Phenytoin sodium lingual spray Amounts preferred most preferred amount amount phenytoin sodium 10-60 15-55 20-40 water 2.5-25 3-20 5-10 ethanol 5-30 7.5-20 9.5-15 propylene glycol 5-30 7.5-20 9.5-15 polyethylene glycol5-30 7.5-20 9.5-15 flavors 1-10 3-8 5-7.5 B. Pheny toin non-polar lingual spray Amounts preferred amount most preferred amount phenytoin 5-45 10-40 15-3 5 migylol 10-50 15-40 15-20 Butane 15-80 30-75 60-70 polyoxyethylated oleic glycerides 10-50 15-40 15-20 flavors 0.1-10 1-8 5-7.5 Prostaglandins A. Carboprost thromethamine lingual spray Amounts preferred amountmost preferred amount carboprost thromethamine0.05-5 0.1-3 0.25-2.5 water 50-95 60-80 65-75 ethanol 5-20 7.5-15 9.5-12.5 polyethylene glycol 5-20 7.5-15 9.5-12.5 sodium chloride 1-20 3-15 4-8 flavors 0.1-5 1-4 2-3 pH is adjusted with sodium hydroxide and/or hydrochloric acid B. Carboprost non-polar lin u~al spray Amounts preferred amountmost preferred amount carboprost 0.05-5 0.1-3 0.25-2.5 migylol 25-50 30-45 35-40 Butane 5-60 10-50 20-35 polyoxyethylated oleic glycerides 25-50 30-45 35-40 flavors 0.1-10 1-8 5-7.5 Neutraceuticals A. Carnitine as bite capsule (contents are a paste) Amounts preferred amountmost preferred amount carnitine arate 6-80 30-70 45-65 fum soya oil 7.5-50 10-40 12.5-35 Soya lecithin 0.001-1.0 0.005-0.5 .O1-0.1 Soya fats 7.5-50 10-40 12.5-35 flavors 1-10 2-8 3-6 B. Valerian as lin y ugual sspra Amounts preferred amountmost preferred amount valerian extract 0.1-10 0.2-7 0.25-5 water 50-95 60-80 65-75 ethanol 5-20 7.5-15 9.5-12.5 polyethylene glycol 5-20 7.5-15 9.5-12.5 flavors 1-10 2-8 3-6 C. Echinacea as bite capsule Amounts preferred amountmost preferred amount echinacea extract 30-85 40-75 45-55 soya oil 7.5-50 10-40 12.5-35 soya lecithin 0.001-1.0 0.005-0.5 .O1-0.1 Soya fats 7.5-50 10-40 12.5-35 flavors 1-10 2-8 3-6 D. Mixtures of ingredients Amounts preferred amountmost preferred amount magnesium oxide 15-40 20-35 25-30 chromium picolinate 0.01-1.0 0.02-0.5 .025-0.75 folic acid .025-3.0 0.05-2.0 0.25-0.5 vitamin B-12 0.01-1.0 0.02-0.5 .025-0.75 vitamin E 15-40 20-35 25-30 Soya oil 10-40 12.5-35 15-20 soya lecithin 0.1-5 0.2-4 0.5-1.5 soya fat 10-40 15-3 5 17.5-20 Sleep Inducers (also CNS active amine) A. Diphenhydramine hydrochloride lin -ug-al sspray Amounts preferred amountmost preferred amount diphenhydramine 3-50. 4-40 5-35 HCl water S-90 10-80 50-75 ethanol 1-80 3-50 5-10 polyethylene glycol 1-80 3-50 S-15 Sorbitol 0.1-5 0.2-4 0.4-1.0 aspartame 0.01-0.5 0.02-0.4 0.04-0.1 flavors 0.1-5 1-4 2-3 Anti-Asthmatics-Bronchodilators A. Isoproterenol Hydrochloride as polar lingual sbrav Amounts preferred amount most preferred amount isoproterenol loride 0.1-10 0.2-7.5 0.5-6 Hydroch water 5-90 10-80 50-75 ethanol . 1-80 3-50 5-10 polyethylene glycol1-80 3-50 5-15 Sorbitol 0.1-5 0.2-4 0.4-1.0 aspartame 0.01-0.5 0.02-0.4 0.04-0.1 flavors 0.1-5 1-4 2-3 B. Terbutaline sulfate as polar lingual spray Amounts preferred amount most preferred amount terbutaline sulfate0.1-10 0.2-7.5 0.5-6 water 5-90 10-80 50-75 ethanol 1-10 2-8 2.5-5 Sorbitol 0.1-5 0.2-4 0.4-1.0 aspartame 0.01-0.5 0.02-0.4 0.04-0.1 flavors 0.1-5 1-4 2-3 C. Terbutaline as non-polar lin ug-al sspray Amounts preferred am ount most preferred amount terbutaline 0.1-10 0.2-7.5 0.5-6 migylol 25-50 30-45 35-40 isobutane 5-60 10-50 20-35 polyoxyethylated oleic glycerides 25-50 30-45 35-40 flavors 0.1-10 1-8 5-7.5 D. Theophylline polar bite capsule Amounts preferred amountmost preferred amount theophylline 5-50 10-40 15-30 polyethylene glycol20-60 25-50 30-40 glycerin 25-50 35-45 30-40 propylene glycol 25-50 35-45 30-40 flavors 0.1-5 1-4 2-3 E. Albuterol sulfate as polar lin u~al spray Amounts preferred amountmost preferred amount albuterol sulfate 0.1-10 0.2-7.5 0.5-6 water 5-90 10-80 50-75 ethanol 1-10 2-8 2.5-5 Sorbitol 0.1-5 0.2-4 0.4-1.0 aspartame 0.01-0.5 0.02-0.4 0.04-0.1 flavors 0.1-5 1-4 2-3 Example 12 Polar solvent formulations using a propellant:
A. Sulfonylurea Amount Preferred AmountMost-Preferred Amount glyburide 0.1-25% 0.5-15% 0.6-10%
Ethanol 40-99% 60-97% 70-97%
Water 0.01-5% 0.1-4% 0.2-2%
Flavors 0.05-10% 0.1-5% 0.1-2.5%
Propellant 2-10% 3-5% 3-4%
B. Prostaglandin E (vasodilator) Amount Preferred AmountMost-Preferred Amount prostaglandin El 0.01-10% 0.1-5% 0.2-3%
Ethanol 10-90% 20-75% 25-50%
Propylene glycol1-90% 5-80% 10-75%
Water 0.01-5% 0.1-4% 0.2-2%
Flavors 0.05-10% 0.1-5% 0.1-2.5%
Propellant 2-10% 3-5% 3-4%
C. Promethazine sleep inducer, ~antiemetic, and CNS active amine) Amount Preferred AmountMost-Preferred Amount promethazine 1-25% 3-15% 5-12%
Ethanol 10-90% 20-75% 25-50%
Propylene glycol 1-90% 5-80% 10-75%
Water 0.01-5% 0.1-4% 0.2-2%
Flavors 0.05-10% 0.1-S% 0.1-2.5%
Propellant 2-10% 3-5% 3-4%
D. Meclizine Amount Preferred Amount Most-Preferred Amount meclizine 1-25% 3-15% 5-12%
Ethanol 1-15% 2-10% 3-6 Propylene glycol20-98% 5-90% 10-85%
Water 0.01-5% 0.1-4% 0.2-2%
Flavors 0.05-10% 0.1-5% 0.1-2.5%
Propellant 2-10% 3-5% 3-4%
In one embodiment the active compound is a nerve impulse inhibitor.
Suitable nerve impulse inhibitors for use in the buccal sprays of the invention include, but are not limited to levobupivacaine, lidocaine, prilocaine, mepivacaine, propofol, rapacuronium bromide, ropivacaine, tubocurarine, atracurium, doxacurium, mivacurium, pancuronium, vecuronium, pipecuronium, rocuronium, and mixtures thereof.
In one embodiment the active compound is an anti-opioid agent. Suitable anti-opioid agents for use in the buccal sprays of the invention include, but are not limited to, naloxone, nalinefene, naltrexone, cholecystokinin, nociceptin, neuropeptide FF, oxytocin, vasopressin, and mixtures thereof.
In one embodiment the active compound is an anti-migraine agent. Suitable anti-migraine agents for use in the buccal sprays of the invention include, but axe not limited to, frovatriptan, zolmitriptan, rizatriptan, almotriptan, eletriptan, naratriptan, alinotriptan, ergotamine, diethylergotamine, sumatriptan, and mixtures thereof.
In one embodiment the active compound is an anti-muscle spasm agent.
Suitable anti-muscle spasm agents for use in the buccal sprays of the invention include, but are not limited to, baclofen, botulinum toxin, carisoprodol, chlorphenesin, chlorzoxazone, cyclobenzaprine, dantrolene, diazepam, metaxalone, methocarbamol, orphenadrine, tizanidine, and mixtures thereof.
In one embodiment the active compound is a pain control agent. Suitable pain control agents for use in the buccal sprays of the invention include, but are not limited to, non-steroidal anti-inflammatory drugs, alfentanil, butorphanol, codeine, dezocine, fentanyl, hydrocodone, hydromorphone, levorphanol, meperidine, methadone, morphine, nalbuphine, oxycodone, oxymorphone, propoxyphene, pentazocine, sufentanil, tramadol, and mixtures thereof.
In one embodiment the active compound is an anesthetic. Suitable anesthetics for use in the buccal sprays of the invention include, but axe not limited to, benzonatate, bupivacaine, desflurane, enflurane, isoflurane, levobupivacaine, lidocaine, mepivacaine, prilocaine, propofol, rapacuronium bromide, ropivacaine, sevoflurane, ltetamine, and mixtures thereof.
7_ In one embodiment the active compound is an anti-inflammatory drug.
Suitable anti-inflammatory drugs for use in the buccal sprays of the invention include, but are not limited to, alosetron, anakinra, beclomethasone, betamethasone, budesonide, clobetasol, celecoxib, cromolyn, desoximetasone, dexamethasone, epinastic, etanercept, etoricoxib, flunisolide, fluocinonide, fluticasone, formoterol, hydrocortisone, hydroxychloroquine, ibudilast, ketotifen, meloxicam, mesalamine, methotrexate, methylprednisolone, mometasone, montelukast, nedocromil, olsala.zine, prednisone, ramatroban, rofecoxib, salsalate, terbutaline, triamcinolone, valdecoxib, zafirlukast, and mixtures thereof.
The formulations of the present invention comprise an active compound or a pharmaceutically acceptable salt thereof. The term "pharmaceutically acceptable salts"
refers to salts prepared from pharmaceutically acceptable non-toxic acids or bases including organic and inorganic acids or bases.
When an active compound of the present invention is acidic, salts may be prepared from pharmaceutically acceptable non-toxic bases. Salts derived from all stable forms of inorganic bases include aluminum, ammonium, calcium, copper, iron, lithium, magnesium, manganese, potassium, sodium, zinc, etc. Particularly preferred are the ammonium, calcium, magnesium, potassium, and sodium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurnng substituted amines, cyclic amines and basic ion-exchange resins such as arginine, betaine, caffeine, choline, N,N dibenzylethylenediamine, diethylamine, 2-diethylarninoethanol, 2-dimethyl-aminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, isopropylamine, lysine, methyl-glucosamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purine, theobromine, triethylamine, trimethylamine, tripropylamine, etc.
When an active compound of the present invention is basic, salts may be prepared from pharmaceutically acceptable non-toxic acids. Such acids include acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethane-sulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, malefic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p-toluenesulfonic, etc. Particularly preferred are citric, hydrobromic, malefic, phosphoric, sulfuric, and tartaric acids.
_S_ In the discussion of methods of treatment herein, reference to the active compounds is meant to also include the pharmaceutically acceptable salts thereof. While certain formulations are set forth herein, the actual amounts to be administered to the mammal or man in need of same are to be determined by the treating physician.
The invention is further defined by reference to the following examples, which are intended to be illustrative and not limiting.
The following are examples of certain classes. All values unless otherwise specified are in weight percent.
_g_ EXAMPLES
Biologically active peptides including peptide hormones A. Cyclosp orine lingualray sp Amounts preferred amountmost preferred amount cyclosporine 5-50 10-35 15-25 water 5-20 7.5-50 9.5-12 ethanol 5-60 7.5-50 10-20 polyethylene 20-60 30-45 35-40 glycol flavors 0.1-5 1-4 2-3 B. C~p orine Non-Polar lingual spray Amounts preferred amount most preferred amount cyclosporine 1-50 3-40 5-30 Migylol 20 25 30-40 Polyoxyethylated 25 30-40 castor oil 20 Butane 25-~0 30-70 33-50 flavors 0.1-5 1-4 2-3 C. Cyclosp orine non-polar bite capsule Amounts preferred amountmost preferred amount cyclosporine 1-35 5-25 10-20 olive oil 25-60 35-55 30-45 polyoxyethylated oleic glycerides25-60 35-55 30-45 flavors 0.1-5 1-4 2-3 D. Cyclos~orine bite ca sule Amounts preferred amountmost preferred amount cyclosporine 5-50 10-35 15-25 polyethylene glycol20-60 30-45 35-40 glycerin 5-30 7.5-25 10-20 propylene glycol 5-30 7.5-25 10-20 flavors 0.1-10 1-8 3-6 E. Sermorelin (as the acetate) lin ual spray Amounts preferred amountmost preferred sermorelin (as the acetate) .O1-5 .1-3 .2-1.0 mannitol 1-25 5-20 10-15 monobasic sodium phosphate, 0.1-5 1-3 1 .5-2.5 dibasic sodium phosphate 0.01-5 .OS-3 0.1-0.5 water ethanol 5-30 7.5-25 9.5-15 polyethylene glycol 20-60 30-45 35-40 propylene glycol 5-25 10-20 12-17 flavors 0.1-5 1-4 2-3 F. Octreotide acetate (Sandostatinl pray lin ug-al ss Amounts preferred amountmost preferred amount octreotide acetate 0.001-0.50.005-0.250 0.01-0.10 acetic acid 1-10 2-8 4-6 sodium acetate 1-10 2-8 4-6 sodium chloride 3-30 .5-25 15-20 flavors 0.1-5 0.5-.4 2-3 ethanol 5-30 7.5-20 9.5-15 water 1 S-95 35-90 65-85 flavors 0.1-5 1-4 2-3 G. Calcitonin-salmon lin ug-al sal spray Amounts preferred amountmost preferred amount calcitonin-salmon 0.001-5 0.005-2 O1-1.5 ethanol 2-15 3-10 7-9.5 water 30-95 50-90 60-80 polyethylene glycol2-15 3-10 7-9.5 sodium chloride 2.5-20 5-15 10-12.5 flavors 0.1-5 1-4 2-3 H. Insulin lispro, lin~praX
Amounts preferred amountmost preferred amount insulin 20-60 4-55 5-50 glycerin 0.1-10 0.25-S 0.1-1.5 dibasic sodium phosphate1-15 2.5-10 4-8 m-cresol, 1-25 5-25 7.5-12.5 zinc oxide 0.01-0.25 .OS-0.15 0.075-0.10 m-cresol 0.1-1 0.2-0.8 0.4-0.6 phenol trace amountstrace amounts trace amounts ethanol 5-20 7.5-15 9-12 water 30-90 40-80 50-75 propylene glycol 5-20 7.5-1 S 9-12 flavors 0.1-5 0.5-3 0.75-2 adjust pH to 7.0-7.8 CI or NaOH
with H
CNS active amines their salts: including and but not limited to tricyclic amines, GABA
analogues, thiazides, agonists and serotonin phenothiazine derivatives, serotonin ant reuptake inhibitors A. Sumatrip tan succinate lin ~ual spray Amounts preferred amount most preferred amount sumatriptan succinate0.5-30 1-20 10-15 ethanol 5-60 7.5-50 10-20 propylene glycol 5-30 7.5-20 10-15 polyethylene glycol0-60 30-45 35-40 water 5-30 7.5-20 10-15 flavors 0.1-5 1-4 2-3 B. Sumatriptan succinate bite capsule Amounts preferred amountmost preferred amount sumatriptan succinate 0.01-5 0.05-3.5 0.075-1.75 polyethylene glycol 25-70 30-60 35-50 glycerin 25-70 30-60 35-50 flavors 0.1-10 1-~ 3-6 C. Clozepine lin ug-al sal spray Amounts preferred amountmost preferred amount clozepine 0.5-30 1-20 10-15 ethanol S-60 7.5-50 10-20 propylene glycol 5-30 7.5-20 10-15 polyethylene glycol 0-60 30-45 35-40 water 5-30 7.5-20 10-15 flavors 0.1-5 1-4 2-3 D. Clozepine non-polar lingual spra~with propellant Amounts preferred amountmost preferred amount clozepine 0.5-30 1-20 10-15 Migylol 20-85 25-70 30-40 Butanol 5-80 30-75 60-70 flavors 0.1-5 1-4 2-3 E. Clozepine non-polar ropellant lingual spray without p Amounts preferred amountmost preferred amount clozepine 0.5-3 0 1-20 10-1 S
Migylol 70-99.5 80-99 85-90 flavors 0.1-5 1-4 2-3 F. Cyclobenzaprine olar lin non-p ual spray _ Amounts preferred amountmost preferred amount cyclobenzaprine 1-20 10-15 (base) 0.5-30 Migylol 20-85 25-70 30-40 Iso-butane15-80 30-75 60-70 flavors 0.1-5 1-4 2-3 G. Dexfenfluramine hydrochloride lin ug-al sspray Amounts preferred amountmost preferred amount dexfenfluramine 5-30 7.5-20 10-15 Hcl ethanol 5-60 7.5-50 10-20 propylene glycol 5-30 7.5-20 10-15 polyethylene glycol 0-60 30-45 35-40 water S-30 7.5-20 10-15 flavors 0.1-5 1-4 2-3 Sulfonylureas A. Glyburide lingual spray Amounts preferred amountmost preferred amount glyburide 0.25-25 0.5-20 0.75-15 ethanol 5-60 -7.5-50 10-20 propylene glycol 5-30 7.5-20 10-15 polyethylene glycol 0-60 30-45 35-40 water 2.5-30 5-20 6-15 flavors 0.1-5 1-4 2-3 B. Glyburide non-polar bite capsule Amounts preferred amountmost preferred amount glyburide 0.01-10 0.025-7.5 0.1-4 olive oil 30-60 35-55 30-50 polyoxyethylated oleic glycerides 30-60 35-55 30-50 flavors 0.1-5 1-4 2-3 Antibiotics anti-fungals and anti-virals A. Zidovudine called azidothymidine(AZTI (Retrovir~]
[formerly non-polar lingual spray Amounts preferred amountmost preferred amount zidovudine 10-50 15-40 25-35 Soya oil 20-85 25-70 30-40 Butane 15-80 30-75 60-70 flavors 0.1-5 1-4 2-3 B. E , hromycin bite capsule bite capsule Amounts preferred amountmost preferred amount erythromycin 25-65 30-50 35-45 polyoxyethylene 5-70 30-60 45-55 glycol glycerin 5-20 7.5-15 10-12.5 flavors 1-10 2-8 3-6 C. Ciprofloxacin hydrochloride bite capsule Amoun ts preferred amount most preferred amount ciprofloxacin hydrochloride 25-6535-55 40-50 glycerin 5-20 7.5-15 10-12.5 polyethylene glycol120-75 30-65 40-60 flavors 1-10 2-8 3-6 D. zidovudine jformerly AZT)~Retrovirl] lingual called spray azidoth idine Amounts preferred amountmost preferred amount zidovudine 10-50 15-40 25-35 water 30-80 40-75 45-70 ethanol 5-20 7.5-15 9.5-12.5 polyethylene glycol5-20 7.5-15 9.5-12.5 flavors 0.1-5 1-4 2-3 Anti-emetics A. Ondansetron hydrochloride lingual spray Amounts preferred amountmost preferred amount ondansetron hydrochloride1-25 2-20 2.5-15 citric acid monohydrate 1-10 2-8 2.5-5 sodium citrate dihydrate 0.5-5 1-4 1.25-2.5 water 1-90 5-85 10-75 ethanol 5-30 7.5-20 9.5-15 propylene glycol 5-30 7.5-20 9.5-15 polyethylene glycol 5-30 7.5-20 9.5-15 flavors 1-10 3-8 5-7.5 B. Dimenh~drinate bite capsule Amountspreferred amount most preferred amount dimenhydrinate 0.5-30 2-25 3-15 glycerin 5-20 7.5-15 10-12.5 polyethylene glycol45-95 50-90 55-85 flavors 1-10 2-8 3-6 C. Dimenhydrinate olar lin ~tg<
p al spray Amountspreferred amount most preferred amount dimenhydrinate 3-50 4-40 5-35 water 5-90 10-80 15-75 ethanol 1-80 3-50 5-10 polyethylene glycol 1-80 3-50 5-15 sorbitol 0.1-5 0.2-40 0.4-1.0 aspartame 0.01-0.50.02-0.4 0.04-0.1 flavors 0.1-5 1-4 2-3 Histamine H-2 receptor antagonists A. Cimetidine hydrochloride bite capsule Amounts preferred amountmost preferred amount cimetidine HCl 10-60 15-55 25-50 glycerin 5-20 7.5-15 10-12.5 polyethylene glycol 20-90 25-85 30-75 flavors 1-10 2-8 3-6 B. Famotidine lingual spray Amounts preferred amountmost preferred amount famotidine 1-35 5-30 7-20 water 2.5-25 3-20 5-10 L-aspartic acid 0.1-20 1-15 5-10 polyethylene glycol 20-97 30-95 50-85 flavors 0.1-10 1-7.5 2-5 C. Famotidine non-polar ng-al sspray lin Amounts preferred amountmost preferred amount famotidine 1-35 5-30 7-20 Soya oil 10-50 15-40 15-20 Butanel 5-80 30-75 45-70 polyoxyethylated oleic glycerides 10-50 15-40 1 S-20 flavors 0.1-5 1-4 2-3 Barbiturates A. Phenytoin sodium lingual spray Amounts preferred most preferred amount amount phenytoin sodium 10-60 15-55 20-40 water 2.5-25 3-20 5-10 ethanol 5-30 7.5-20 9.5-15 propylene glycol 5-30 7.5-20 9.5-15 polyethylene glycol5-30 7.5-20 9.5-15 flavors 1-10 3-8 5-7.5 B. Pheny toin non-polar lingual spray Amounts preferred amount most preferred amount phenytoin 5-45 10-40 15-3 5 migylol 10-50 15-40 15-20 Butane 15-80 30-75 60-70 polyoxyethylated oleic glycerides 10-50 15-40 15-20 flavors 0.1-10 1-8 5-7.5 Prostaglandins A. Carboprost thromethamine lingual spray Amounts preferred amountmost preferred amount carboprost thromethamine0.05-5 0.1-3 0.25-2.5 water 50-95 60-80 65-75 ethanol 5-20 7.5-15 9.5-12.5 polyethylene glycol 5-20 7.5-15 9.5-12.5 sodium chloride 1-20 3-15 4-8 flavors 0.1-5 1-4 2-3 pH is adjusted with sodium hydroxide and/or hydrochloric acid B. Carboprost non-polar lin u~al spray Amounts preferred amountmost preferred amount carboprost 0.05-5 0.1-3 0.25-2.5 migylol 25-50 30-45 35-40 Butane 5-60 10-50 20-35 polyoxyethylated oleic glycerides 25-50 30-45 35-40 flavors 0.1-10 1-8 5-7.5 Neutraceuticals A. Carnitine as bite capsule (contents are a paste) Amounts preferred amountmost preferred amount carnitine arate 6-80 30-70 45-65 fum soya oil 7.5-50 10-40 12.5-35 Soya lecithin 0.001-1.0 0.005-0.5 .O1-0.1 Soya fats 7.5-50 10-40 12.5-35 flavors 1-10 2-8 3-6 B. Valerian as lin y ugual sspra Amounts preferred amountmost preferred amount valerian extract 0.1-10 0.2-7 0.25-5 water 50-95 60-80 65-75 ethanol 5-20 7.5-15 9.5-12.5 polyethylene glycol 5-20 7.5-15 9.5-12.5 flavors 1-10 2-8 3-6 C. Echinacea as bite capsule Amounts preferred amountmost preferred amount echinacea extract 30-85 40-75 45-55 soya oil 7.5-50 10-40 12.5-35 soya lecithin 0.001-1.0 0.005-0.5 .O1-0.1 Soya fats 7.5-50 10-40 12.5-35 flavors 1-10 2-8 3-6 D. Mixtures of ingredients Amounts preferred amountmost preferred amount magnesium oxide 15-40 20-35 25-30 chromium picolinate 0.01-1.0 0.02-0.5 .025-0.75 folic acid .025-3.0 0.05-2.0 0.25-0.5 vitamin B-12 0.01-1.0 0.02-0.5 .025-0.75 vitamin E 15-40 20-35 25-30 Soya oil 10-40 12.5-35 15-20 soya lecithin 0.1-5 0.2-4 0.5-1.5 soya fat 10-40 15-3 5 17.5-20 Sleep Inducers (also CNS active amine) A. Diphenhydramine hydrochloride lin -ug-al sspray Amounts preferred amountmost preferred amount diphenhydramine 3-50. 4-40 5-35 HCl water S-90 10-80 50-75 ethanol 1-80 3-50 5-10 polyethylene glycol 1-80 3-50 S-15 Sorbitol 0.1-5 0.2-4 0.4-1.0 aspartame 0.01-0.5 0.02-0.4 0.04-0.1 flavors 0.1-5 1-4 2-3 Anti-Asthmatics-Bronchodilators A. Isoproterenol Hydrochloride as polar lingual sbrav Amounts preferred amount most preferred amount isoproterenol loride 0.1-10 0.2-7.5 0.5-6 Hydroch water 5-90 10-80 50-75 ethanol . 1-80 3-50 5-10 polyethylene glycol1-80 3-50 5-15 Sorbitol 0.1-5 0.2-4 0.4-1.0 aspartame 0.01-0.5 0.02-0.4 0.04-0.1 flavors 0.1-5 1-4 2-3 B. Terbutaline sulfate as polar lingual spray Amounts preferred amount most preferred amount terbutaline sulfate0.1-10 0.2-7.5 0.5-6 water 5-90 10-80 50-75 ethanol 1-10 2-8 2.5-5 Sorbitol 0.1-5 0.2-4 0.4-1.0 aspartame 0.01-0.5 0.02-0.4 0.04-0.1 flavors 0.1-5 1-4 2-3 C. Terbutaline as non-polar lin ug-al sspray Amounts preferred am ount most preferred amount terbutaline 0.1-10 0.2-7.5 0.5-6 migylol 25-50 30-45 35-40 isobutane 5-60 10-50 20-35 polyoxyethylated oleic glycerides 25-50 30-45 35-40 flavors 0.1-10 1-8 5-7.5 D. Theophylline polar bite capsule Amounts preferred amountmost preferred amount theophylline 5-50 10-40 15-30 polyethylene glycol20-60 25-50 30-40 glycerin 25-50 35-45 30-40 propylene glycol 25-50 35-45 30-40 flavors 0.1-5 1-4 2-3 E. Albuterol sulfate as polar lin u~al spray Amounts preferred amountmost preferred amount albuterol sulfate 0.1-10 0.2-7.5 0.5-6 water 5-90 10-80 50-75 ethanol 1-10 2-8 2.5-5 Sorbitol 0.1-5 0.2-4 0.4-1.0 aspartame 0.01-0.5 0.02-0.4 0.04-0.1 flavors 0.1-5 1-4 2-3 Example 12 Polar solvent formulations using a propellant:
A. Sulfonylurea Amount Preferred AmountMost-Preferred Amount glyburide 0.1-25% 0.5-15% 0.6-10%
Ethanol 40-99% 60-97% 70-97%
Water 0.01-5% 0.1-4% 0.2-2%
Flavors 0.05-10% 0.1-5% 0.1-2.5%
Propellant 2-10% 3-5% 3-4%
B. Prostaglandin E (vasodilator) Amount Preferred AmountMost-Preferred Amount prostaglandin El 0.01-10% 0.1-5% 0.2-3%
Ethanol 10-90% 20-75% 25-50%
Propylene glycol1-90% 5-80% 10-75%
Water 0.01-5% 0.1-4% 0.2-2%
Flavors 0.05-10% 0.1-5% 0.1-2.5%
Propellant 2-10% 3-5% 3-4%
C. Promethazine sleep inducer, ~antiemetic, and CNS active amine) Amount Preferred AmountMost-Preferred Amount promethazine 1-25% 3-15% 5-12%
Ethanol 10-90% 20-75% 25-50%
Propylene glycol 1-90% 5-80% 10-75%
Water 0.01-5% 0.1-4% 0.2-2%
Flavors 0.05-10% 0.1-S% 0.1-2.5%
Propellant 2-10% 3-5% 3-4%
D. Meclizine Amount Preferred Amount Most-Preferred Amount meclizine 1-25% 3-15% 5-12%
Ethanol 1-15% 2-10% 3-6 Propylene glycol20-98% 5-90% 10-85%
Water 0.01-5% 0.1-4% 0.2-2%
Flavors 0.05-10% 0.1-5% 0.1-2.5%
Propellant 2-10% 3-5% 3-4%
Claims (55)
What is claimed is:
1. A propellant free buccal spray composition for transmucosal administration of a pharmacologically active compound comprising:
an active compound in an amount of between 0.001 and 60 percent by weight of the total composition selected from the group consisting of anti-opioid agents, anti-migraine agents, pain control agents, anesthetics, and mixtures thereof; and a polar solvent in an amount between 30 and 99 percent by weight of the total composition.
an active compound in an amount of between 0.001 and 60 percent by weight of the total composition selected from the group consisting of anti-opioid agents, anti-migraine agents, pain control agents, anesthetics, and mixtures thereof; and a polar solvent in an amount between 30 and 99 percent by weight of the total composition.
2. The composition of claim 1, further comprising a flavoring agent in an amount of between 0.1 and 10 percent by weight of the total composition.
3. The composition of claim 2, wherein the polar solvent is present in an amount between 37 and 98 percent by weight of the total composition, the active compound is present in an amount between 0.005 and 55 percent by weight of the total composition, and the flavoring agent is present in an amount between 0.5 and 8 percent by weight of the total composition.
4. The composition of claim 3, wherein the polar solvent is present in an amount between 60 and 97 percent by weight of the total composition, the active compound is present in an amount between 0.01 and 40 percent by weight of the total composition, and the flavoring agent is present in an amount between 0.75 and 7.5 percent by weight of the total composition.
5. The composition of claim 1, wherein the polar solvent is selected from the group consisting of polyethylene glycols having a molecular weight between 400 and 1000, C2 to C8 mono- and poly-alcohols, and C7 to C18 alcohols of linear or branched configuration.
6. The composition of claim 1, wherein the polar solvent comprises aqueous polyethylene glycol.
7. The composition of claim 1, wherein the polar solvent comprises aqueous ethanol.
8. The composition of claim 1, wherein the active compound is an anti-opioid agent selected from the group consisting of naloxone, nalmefene, naltrexone, cholecystokinin, nociceptin, neuropeptide FF, oxytocin, vasopressin, and mixtures thereof.
9. The composition of claim 1, wherein the active compound is an anti-migraine agent selected from the group consisting of frovatriptan, zolmitriptan, rizatriptan, almotriptan, eletriptan, naratriptan, almotriptan, ergotamine, diethylergotamine, sumatriptan, and mixtures thereof.
10. The composition of claim 1, wherein the active compound is a pain control agent selected from the group consisting of non-steroidal anti-inflammatory drugs, alfentanil, butorphanol, codeine, dezocine, fentanyl, hydrocodone, hydromorphone, levorphanol, meperidine, methadone, morphine, nalbuphine, oxycodone, oxymorphone, propoxyphene, pentazocine, sufentanil, tramadol, and mixtures thereof.
11. The composition of claim 1, wherein the active compound is an anesthetic selected from the group consisting of benzonatate, bupivacaine, desflurane, enflurane, isoflurane, levobupivacaine, lidocaine, mepivacaine, prilocaine, propofol, rapacuronium bromide, ropivacaine, sevoflurane, ketamine, and mixtures thereof.
12. The composition of claim 2, wherein the flavoring agent is selected from the group consisting of synthetic or natural oil of peppermint, oil of spearmint, citrus oil, fruit flavors, sweeteners, and mixtures thereof.
13. A method of administering a pharmacologically active compound to a mammal comprising spraying the oral mucosa of the mammal with the composition of claim 1.
14. The method of claim 13, wherein the amount of the spray is predetermined.
15. A buccal spray composition for transmucosal administration of a pharmacologically active compound comprising:
an active compound in an amount of between 0.1 and 25 percent by weight of the total composition selected from the group consisting of anti-opioid agents, anti-migraine agents, pain control agents, anesthetics, and mixtures thereof;
a polar solvent in an amount between 10 and 97 percent by weight of the total composition; and a propellant in an amount between 2 and 10 percent by weight of the total composition, wherein said propellant is a C3 to C8 hydrocarbon of linear or branched configuration.
an active compound in an amount of between 0.1 and 25 percent by weight of the total composition selected from the group consisting of anti-opioid agents, anti-migraine agents, pain control agents, anesthetics, and mixtures thereof;
a polar solvent in an amount between 10 and 97 percent by weight of the total composition; and a propellant in an amount between 2 and 10 percent by weight of the total composition, wherein said propellant is a C3 to C8 hydrocarbon of linear or branched configuration.
16. The composition of claim 15, further comprising a flavoring agent in an amount between 0.05 and 10 percent by weight of the total composition.
17. The composition of claim 16, wherein the polar solvent is present in an amount between 20 and 97 percent by weight of the total composition, the active compound is present in an amount between 0.1 and 15 percent by weight of the total composition, the propellant is present in an amount between 2 and 5 percent by weight of the composition, and the flavoring agent is present in an amount between 0.1 and 5 percent by weight of the total composition.
18. The composition of claim 17, wherein the polar solvent is present in an amount between 25 and 97 percent by weight of the total composition, the active compound is present in an amount between 0.2 and 25 percent by weight of the total composition, the propellant is present in an amount between 2 and 4 percent by weight of the composition, and flavoring agent is present in an amount between 0.1 and 2.5 percent by weight of the total composition.
19. The composition of claim 15, wherein the polar solvent is selected from the group consisting of polyethyleneglycols having a molecular weight between 400 and 1000, C2 to C8 mono- and poly-alcohols, and C7 to C18 alcohols of linear or branched configuration.
20. The composition of claim 19, wherein the polar solvent comprises aqueous polyethylene glycol.
21. The composition of claim 19, wherein the polar solvent comprises aqueous ethanol.
22. The composition of claim 15, wherein the active compound is an anti-opioid agent selected from the group consisting of naloxone, nalmefene, naltrexone, cholecystokinin, nociceptin, neuropeptide FF, oxytocin, vasopressin, and mixtures thereof.
23. The composition of claim 15, wherein the active compound is an anti-migraine agent selected from the group consisting of frovatriptan, zolmitriptan, rizatriptan, almotriptan, eletriptan, naratriptan, almotriptan, ergotamine, diethylergotamine, sumatriptan, and mixtures thereof.
24. The composition of claim 15, wherein the active compound is a pain control agent selected from the group consisting of non-steroidal anti-inflammatory drugs, alfentanil, butorphanol, codeine, dezocine, fentanyl, hydrocodone, hydromorphone, levorphanol, meperidine, methadone, morphine, nalbuphine, oxycodone, oxymorphone, propoxyphene, pentazocine, sufentanil, tramadol, and mixtures thereof.
25. The composition of claim 15, wherein the active compound is an anesthetic selected from the group consisting of benzonatate, bupivacaine, desflurane, enflurane, isoflurane, levobupivacaine, lidocaine, mepivacaine, prilocaine, propofol, rapacuronium bromide, ropivacaine, sevoflurane, ketamine, and mixtures thereof.
26. The composition of claim 16, wherein the flavoring agent is selected from the group consisting of synthetic or natural oil of peppermint, oil of spearmint, citrus oil, fruit flavors, sweeteners, and mixtures thereof.
27. The composition of claim 15, wherein the propellant is selected from the group consisting of propane, N-butane, iso-butane, N-pentane, iso-pentane, neo-pentane, and mixtures thereof.
28. A method of administering a pharmacologically active compound to a mammal comprising spraying the oral mucosa of the mammal with the composition of claim 15.
29. The method of claim 28, wherein the amount of the spray is predetermined.
30. A propellant free buccal spray composition for transmucosal administration of a pharmacologically active compound comprising:
an active compound in an amount between 0.005 and 55 percent by weight of the total composition selected from the group consisting of anti-opioid agents, anti-migraine agents, pain control agents, anesthetics, and mixtures thereof; and a non-polar solvent in an amount between 30 and 99 percent by weight of the total composition.
an active compound in an amount between 0.005 and 55 percent by weight of the total composition selected from the group consisting of anti-opioid agents, anti-migraine agents, pain control agents, anesthetics, and mixtures thereof; and a non-polar solvent in an amount between 30 and 99 percent by weight of the total composition.
31. The composition of claim 30, further comprising a flavoring agent in an amount between 0.1 and 10 percent by weight of the total composition.
32. The composition of claim 30, wherein the active compound is an anti-opioid agent selected from the group consisting of naloxone, nalmefene, naltrexone, cholecystokinin, nociceptin, neuropeptide FF, oxytocin, vasopressin, and mixtures thereof.
33. The composition of claim 30, wherein the active compound is an anti-migraine agent selected from the group consisting of frovatriptan, zolmitriptan, rizatriptan, almotriptan, eletriptan, naratriptan, almotriptan, ergotamine, diethylergotamine, sumatriptan, and mixtures thereof.
34. The composition of claim 30, wherein the active compound is a pain control agent selected from the group consisting of non-steroidal anti-inflammatory drugs, alfentanil, butorphanol, codeine, dezocine, fentanyl, hydrocodone, hydromorphone, levorphanol, meperidine, methadone, morphine, nalbuphine, oxycodone, oxymorphone, propoxyphene, pentazocine, sufentanil, tramadol, and mixtures thereof.
35. The composition of claim 30, wherein the active compound is an anesthetic selected from the group consisting of benzonatate, bupivacaine, desflurane, enflurane, isoflurane, levobupivacaine, lidocaine, mepivacaine, prilocaine, propofol, rapacuronium bromide, ropivacaine, sevoflurane, ketamine, and mixtures thereof.
36. The composition of claim 31, wherein the flavoring agent is selected from the group consisting of synthetic or natural oil of peppermint, oil of spearmint, citrus oil, fruit flavors, sweeteners, and mixtures thereof.
37. The composition of claim 30, wherein the solvent is selected from the group consisting of (C2-C24) fatty acid (C2-C6) esters, C7-C18 hydrocarbons of linear or branched configuration, C2-C6 alkanoyl esters, and triglycerides of C2-C6 carboxylic acids.
38. The composition of claim 37, wherein the solvent is miglyol.
39. A method of administering a pharmacologically active compound to a mammal comprising spraying the oral mucosa of the mammal with the composition of claim 30.
40. The method of claim 39, wherein the amount of the spray is predetermined.
41. A buccal spray composition for transmucosal administration of a pharmacologically active compound comprising:
an active compound in an amount between 0.05 and 50 percent by weight of the total composition selected from the group consisting of anti-opioid agents, anti-migraine agents, pain control agents, anesthetics, and mixtures thereof; and a non-polar solvent in an amount between 19 and 85 percent by weight of the total composition; and a propellant in an amount between 5 and 80 percent by weight of the total composition, wherein said propellant is a C3 to C8 hydrocarbon of linear or brancehed configuration.
an active compound in an amount between 0.05 and 50 percent by weight of the total composition selected from the group consisting of anti-opioid agents, anti-migraine agents, pain control agents, anesthetics, and mixtures thereof; and a non-polar solvent in an amount between 19 and 85 percent by weight of the total composition; and a propellant in an amount between 5 and 80 percent by weight of the total composition, wherein said propellant is a C3 to C8 hydrocarbon of linear or brancehed configuration.
42. The composition of claim 41, further comprising a flavoring agent in an amount of between 0.1 and 10 percent by weight of the total composition.
43. The composition of claim 42, wherein the flavoring agent is selected from the group consisting of synthetic or natural oil of peppermint, oil of spearmint, citrus oil, fruit flavors, sweeteners, and mixtures thereof.
44. A buccal spray composition for transmucosal administration of a pharmacologically active compound comprising:
an active compound in an amount between 0.01 and 40 percent by weight of the total composition selected from the group consisting of anti-opioid agents, anti-migraine agents, pain control agents, anesthetics, and mixtures thereof; and a non-polar solvent in an amount between 25 and 89 percent by weight of the total composition;
a propellant in an amount between 10 and 70 percent by weight of the total composition, wherein said propellant is a C3 to C8 hydrocarbon of linear or brancehed configuration; and A flavoring agent is present in an amount between 1 and 8 percent by weight of the total composition.
an active compound in an amount between 0.01 and 40 percent by weight of the total composition selected from the group consisting of anti-opioid agents, anti-migraine agents, pain control agents, anesthetics, and mixtures thereof; and a non-polar solvent in an amount between 25 and 89 percent by weight of the total composition;
a propellant in an amount between 10 and 70 percent by weight of the total composition, wherein said propellant is a C3 to C8 hydrocarbon of linear or brancehed configuration; and A flavoring agent is present in an amount between 1 and 8 percent by weight of the total composition.
45. The composition of claim 44, wherein the propellant is present in an amount between 20 and 70 percent by weight of the total composition, the non-polar solvent is present in an amount between 25 and 75 percent by weight of the total composition, the active compound is present in an amount from between 0.25 and 35 percent by weight of the total composition, and the flavoring agent is present in an amount between 2 and 7.5 percent by weight of the total composition.
46. The composition of claim 42, wherein the propellant is selected from the group consisting of propane, n-butane, iso-butane, n-pentane, iso-pentane, neo-pentane, and mixtures thereof.
47. The composition of claim 46, wherein the propellant is n-butane or iso-butane and has a water content of not more than 0.2 percent and a concentration of oxidizing agents, reducing agents, Lewis acids, and Lewis bases of less than 0.1 percent.
48. The composition of claim 41, wherein the solvent is selected from the group consisting of (C2-C24) fatty acid (C2-C6) esters, C7-C18 hydrocarbons of linear or branched configuration, C2-C6 alkanoyl esters, and triglycerides of C2-C6 carboxylic acids.
49. The composition of claim 48, wherein the solvent is miglyol.
50. The composition of claim 41, wherein the active compound is an anti-opioid agent selected from the group consisting of naloxone, nalmefene, naltrexone, cholecystokinin, nociceptin, neuropeptide FF, oxytocin, vasopressin, and mixtures thereof.
51. The composition of claim 41, wherein the active compound is an anti-migraine agent selected from the group consisting of frovatriptan, zolmitriptan, rizatriptan, almotriptan, eletriptan, naratriptan, almotriptan, ergotamine, diethylergotamine, sumatriptan, and mixtures thereof.
52. The composition of claim 41, wherein the active compound is a pain control agent selected from the group consisting of non-steroidal anti-inflammatory drugs, alfentanil, butorphanol, codeine, dezocine, fentanyl, hydrocodone, hydromorphone, levorphanol, meperidine, methadone, morphine, nalbuphine, oxycodone, oxymorphone, propoxyphene, pentazocine, sufentanil, tramadol, and mixtures thereof.
53. The composition of claim 41, wherein the active compound is an anesthetic selected from the group consisting of benzonatate, bupivacaine, desflurane, enflurane, isoflurane, levobupivacaine, lidocaine, mepivacaine, prilocaine, propofol, rapacuronium bromide, ropivacaine, sevoflurane, ketamine, and mixtures thereof.
54. A method of administering a pharmacologically active compound to a mammal comprising spraying the oral mucosa of the mammal with the composition of claim 41.
55. The method of claim 54, wherein the amount of the spray is predetermined.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/230,059 | 2002-08-29 | ||
US10/230,059 US20030185761A1 (en) | 1997-10-01 | 2002-08-29 | Buccal, polar and non-polar spray or capsule containing drugs for treating pain |
PCT/US2003/026859 WO2004043428A2 (en) | 2002-08-29 | 2003-08-27 | Buccal, polar and non-polar spray or capsule containing drugs for treating pain |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2497268A1 true CA2497268A1 (en) | 2004-05-27 |
Family
ID=32312002
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002497268A Abandoned CA2497268A1 (en) | 2002-08-29 | 2003-08-27 | Buccal, polar and non-polar spray or capsule containing drugs for treating pain |
Country Status (7)
Country | Link |
---|---|
US (4) | US20030185761A1 (en) |
EP (1) | EP1539107A2 (en) |
JP (1) | JP2006505611A (en) |
AU (1) | AU2003296899A1 (en) |
CA (1) | CA2497268A1 (en) |
NZ (1) | NZ539284A (en) |
WO (1) | WO2004043428A2 (en) |
Families Citing this family (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030095926A1 (en) * | 1997-10-01 | 2003-05-22 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract |
US20030185761A1 (en) * | 1997-10-01 | 2003-10-02 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating pain |
US20030077229A1 (en) * | 1997-10-01 | 2003-04-24 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs |
US7632517B2 (en) * | 1997-10-01 | 2009-12-15 | Novadel Pharma Inc. | Buccal, polar and non-polar spray containing zolpidem |
US20030077228A1 (en) * | 1997-10-01 | 2003-04-24 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating endocrine disorders |
US20090162300A1 (en) * | 1997-10-01 | 2009-06-25 | Dugger Iii Harry A | Buccal, polar and non-polar spray containing alprazolam |
US20050281752A1 (en) * | 1997-10-01 | 2005-12-22 | Dugger Harry A Iii | Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system |
US20030082107A1 (en) * | 1997-10-01 | 2003-05-01 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating an infectious disease or cancer |
US20030077227A1 (en) * | 1997-10-01 | 2003-04-24 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system |
US20040141923A1 (en) * | 1997-10-01 | 2004-07-22 | Dugger Harry A. | Buccal, polar and non-polar spray containing alprazolam |
US20040136913A1 (en) * | 1997-10-01 | 2004-07-15 | Dugger Harry A. | Buccal, polar and non-polar spray containing sumatriptan |
US20030190286A1 (en) * | 1997-10-01 | 2003-10-09 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating allergies or asthma |
US20040136915A1 (en) * | 1997-10-01 | 2004-07-15 | Dugger Harry A. | Buccal, polar and non-polar spray containing atropine |
EP1029536B1 (en) * | 1997-10-01 | 2007-11-28 | Novadel Pharma Inc. | Buccal non-polar spray |
US20040136914A1 (en) * | 1997-10-01 | 2004-07-15 | Dugger Harry A. | Buccal, polar and non-polar spray containing ondansetron |
US20030095927A1 (en) * | 1997-10-01 | 2003-05-22 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating muscular and skeletal disorders |
US20030095925A1 (en) * | 1997-10-01 | 2003-05-22 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders |
US20050163719A1 (en) * | 1997-10-01 | 2005-07-28 | Dugger Harry A.Iii | Buccal, polar and non-polar spray containing diazepam |
US20050180923A1 (en) * | 1997-10-01 | 2005-08-18 | Dugger Harry A.Iii | Buccal, polar and non-polar spray containing testosterone |
US20050287075A1 (en) * | 1997-10-01 | 2005-12-29 | Dugger Harry A Iii | Buccal, polar and non-polar spray or capsule containing drugs for treating pain |
US20050002867A1 (en) * | 1997-10-01 | 2005-01-06 | Novadel Pharma Inc. | Buccal, polar and non-polar sprays containing propofol |
EP1608372A2 (en) * | 2003-03-11 | 2005-12-28 | Arakis Ltd. | Compositions containing fentanyl |
US20060062812A1 (en) * | 2003-03-11 | 2006-03-23 | Calvin Ross | Novel compositions |
NZ527142A (en) * | 2003-07-23 | 2006-03-31 | Douglas Pharmaceuticals Ltd | A stable suspension formulation |
EP1715853A4 (en) * | 2004-02-17 | 2012-07-18 | Transcept Pharmaceuticals Inc | Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof |
EP1765300A2 (en) * | 2004-06-10 | 2007-03-28 | Duramed Pharmaceuticals, Inc. | Formulations of sumatriptan for absorption across biological membranes, and methods of making and using the same |
EP2767163A1 (en) | 2005-02-17 | 2014-08-20 | Abbott Laboratories | Transmucosal administration of drug compositions for treating and preventing disorders in animals |
US20060193784A1 (en) * | 2005-02-25 | 2006-08-31 | Peter Crooks | Scopolamine sublingual spray for the treatment of motion sickness |
WO2006105205A1 (en) * | 2005-03-29 | 2006-10-05 | University Of Kentucky Research Foundation | Sublingual spray for the treatment of pain |
US20060281783A1 (en) * | 2005-05-25 | 2006-12-14 | Transoral Pharmaceuticals, Inc. | Compositions and methods of treating middle-of-the night insomnia |
US20070287740A1 (en) * | 2005-05-25 | 2007-12-13 | Transcept Pharmaceuticals, Inc. | Compositions and methods of treating middle-of-the night insomnia |
US20070225322A1 (en) * | 2005-05-25 | 2007-09-27 | Transoral Pharmaceuticals, Inc. | Compositions and methods for treating middle-of-the night insomnia |
CA2620364A1 (en) | 2005-08-26 | 2007-03-01 | David C. Yeomans | Methods for treatment of headaches by administration of oxytocin |
US8753308B2 (en) | 2006-01-06 | 2014-06-17 | Acelrx Pharmaceuticals, Inc. | Methods for administering small volume oral transmucosal dosage forms using a dispensing device |
US9066847B2 (en) | 2007-01-05 | 2015-06-30 | Aceirx Pharmaceuticals, Inc. | Storage and dispensing devices for administration of oral transmucosal dosage forms |
US8252328B2 (en) | 2006-01-06 | 2012-08-28 | Acelrx Pharmaceuticals, Inc. | Bioadhesive drug formulations for oral transmucosal delivery |
US8202535B2 (en) | 2006-01-06 | 2012-06-19 | Acelrx Pharmaceuticals, Inc. | Small-volume oral transmucosal dosage forms |
US8252329B2 (en) | 2007-01-05 | 2012-08-28 | Acelrx Pharmaceuticals, Inc. | Bioadhesive drug formulations for oral transmucosal delivery |
US8535714B2 (en) | 2006-01-06 | 2013-09-17 | Acelrx Pharmaceuticals, Inc. | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
US9289583B2 (en) | 2006-01-06 | 2016-03-22 | Acelrx Pharmaceuticals, Inc. | Methods for administering small volume oral transmucosal dosage forms using a dispensing device |
US8865743B2 (en) | 2006-01-06 | 2014-10-21 | Acelrx Pharmaceuticals, Inc. | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
US8357114B2 (en) | 2006-01-06 | 2013-01-22 | Acelrx Pharmaceuticals, Inc. | Drug dispensing device with flexible push rod |
BRPI0707235B8 (en) | 2006-01-25 | 2021-05-25 | Insys Therapeutics Inc | sublingual fentanyl formulation without propellant, and, unit dose device for sublingual administration of a sublingual fentanyl formulation |
CA2649895C (en) * | 2006-04-19 | 2013-03-26 | Novadel Pharma Inc. | Stable hydroalcoholic oral spray formulations and methods |
AU2006343439B2 (en) * | 2006-05-08 | 2013-05-16 | Arturo Solis Herrera | The use of nicotine, analogues thereof, precursors thereof or derivatives thereof in the treatment of various pathological processes capable of improvement with a-MSH administered in prophylactic or therapeutic form |
US20070260491A1 (en) * | 2006-05-08 | 2007-11-08 | Pamela Palmer | System for delivery and monitoring of administration of controlled substances |
US20070299687A1 (en) * | 2006-06-23 | 2007-12-27 | Pamela Palmer | Inpatient system for patient-controlled delivery of oral transmucosal medications dosed as needed |
CA2659245A1 (en) * | 2006-07-28 | 2008-01-31 | Novadel Pharma Inc. | Anti-migraine oral spray formulations and methods |
ES2573253T3 (en) * | 2006-09-20 | 2016-06-06 | The Board Of Regents Of The University Of Texas System | Methods for the supply of volatile anesthetics for regional anesthesia and / or pain relief |
EP2124556B1 (en) | 2006-10-09 | 2014-09-03 | Charleston Laboratories, Inc. | Pharmaceutical compositions |
EP2124897A4 (en) * | 2006-12-22 | 2012-05-09 | Novadel Pharma Inc | Stable anti-nausea oral spray formulations and methods |
JP2010526837A (en) * | 2007-05-10 | 2010-08-05 | ノヴァデル ファーマ インコーポレイテッド | Anti-insomnia compositions and methods |
DK2180844T3 (en) * | 2007-08-02 | 2018-04-23 | Insys Dev Co Inc | SUBLINGUAL FENTANYLSPRAY |
US7985325B2 (en) * | 2007-10-30 | 2011-07-26 | Novellus Systems, Inc. | Closed contact electroplating cup assembly |
DE102007063040A1 (en) | 2007-12-28 | 2009-07-23 | Atotech Deutschland Gmbh | Production of micro-reactors comprises coating a plate having channels and joint regions on the surface with a joining layer, applying a layer made from a suspension containing catalyst support particles and further processing |
EP2240022B1 (en) | 2008-01-09 | 2016-12-28 | Charleston Laboratories, Inc. | Bilayered tablets comprising oxycodone and promethazine |
DK2244737T3 (en) * | 2008-01-22 | 2019-07-08 | Univ Texas | Volatile anesthetic compositions comprising extraction solvents for regional anesthesia and / or pain relief |
WO2009094460A2 (en) | 2008-01-22 | 2009-07-30 | Vapogenix, Inc. | Volatile anesthetic compositions and methods of use |
US8945592B2 (en) * | 2008-11-21 | 2015-02-03 | Acelrx Pharmaceuticals, Inc. | Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same |
ES2642281T3 (en) * | 2009-05-29 | 2017-11-16 | Morishita Jintan Co., Ltd. | Oral medicinal composition and oral medicinal capsule having the composition encapsulated therein |
EP2451274B1 (en) | 2009-07-08 | 2017-10-04 | Charleston Laboratories, Inc. | Pharmaceutical compositions |
US11337962B2 (en) | 2009-09-25 | 2022-05-24 | Upsher-Smith Laboratories, Llc | Formulations comprising triptan compounds |
US9211282B2 (en) | 2009-09-25 | 2015-12-15 | Dr. Reddy's Laboratories Ltd. | Formulations comprising triptan compounds |
US8357398B2 (en) * | 2009-10-21 | 2013-01-22 | Alitair Pharmaceuticals Inc. | Benzonatate compositions and methods of use |
CA2782056C (en) | 2009-11-25 | 2021-03-09 | Arisgen Sa | Mucosal delivery of peptides |
GB2476494A (en) * | 2009-12-24 | 2011-06-29 | Norwich Pharma Technologies Ltd | Formulation for the sublingual delivery of sufentanil |
EP2526971A1 (en) | 2011-05-25 | 2012-11-28 | ArisGen SA | Mucosal delivery of drugs |
FR2994844B1 (en) * | 2012-08-31 | 2015-01-02 | Assist Publ Hopitaux De Paris | GELIFYING FORMULATION BASED ON KETAMINE |
WO2014143964A2 (en) * | 2013-03-15 | 2014-09-18 | Vapogenix, Inc. | Novel analgesic compositions |
US9433644B2 (en) | 2013-07-25 | 2016-09-06 | Rutgilli Pharmaceuticals, Llc | Formulations and methods for treating oral inflammation, injury, or pain |
US10195153B2 (en) | 2013-08-12 | 2019-02-05 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
US10172797B2 (en) | 2013-12-17 | 2019-01-08 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
WO2015095644A1 (en) | 2013-12-20 | 2015-06-25 | AntiOP, Inc. | Intranasal naloxone compositions and methods of making and using same |
ES2809458T3 (en) | 2014-07-17 | 2021-03-04 | Pharmaceutical Manufacturing Res Services Inc | Liquid filled, abuse deterrent and immediate release dosage form |
JP2017531026A (en) | 2014-10-20 | 2017-10-19 | ファーマシューティカル マニュファクチュアリング リサーチ サービシズ,インコーポレーテッド | Sustained release abuse deterrent liquid filler form |
MY187877A (en) | 2014-12-23 | 2021-10-26 | Acelrx Pharmaceuticals Inc | Systems, devices and methods for dispensing oral transmucosal dosage forms |
LT3242676T (en) | 2015-01-07 | 2024-01-25 | Tonix Pharma Limited | Magnesium-containing oxytocin formulations and methods of use |
CN105193774B (en) * | 2015-09-21 | 2018-01-16 | 山东新时代药业有限公司 | A kind of sevoflurane inhalant |
JP2019507181A (en) | 2016-03-04 | 2019-03-14 | チャールストン ラボラトリーズ,インコーポレイテッド | Pharmaceutical composition |
US11331271B2 (en) | 2016-05-27 | 2022-05-17 | The Johns Hopkins University | Buccal, sublingual and intranasal delivery of fospropofol |
US10265309B2 (en) * | 2016-05-27 | 2019-04-23 | Insys Development Company, Inc. | Sublingual opioid formulations containing naloxone |
EP3773497B1 (en) | 2018-04-09 | 2023-10-18 | Elgan Pharma Ltd. | Oxytocin compositions and methods of use |
CN109044973A (en) * | 2018-11-02 | 2018-12-21 | 广东药科大学 | A kind of swelling and pain relieving is spraying |
CN113350277A (en) * | 2021-06-30 | 2021-09-07 | 广东科伦药业有限公司 | Mesalazine gargle for treating chemotherapy oral mucositis and preparation method thereof |
Family Cites Families (107)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE632504A (en) | 1962-05-24 | |||
US3304230A (en) | 1963-02-18 | 1967-02-14 | Revlon | Liquid aerosol propellant solutions of fatty acid salts of physiologically active amines |
SU432703A3 (en) | 1971-08-24 | 1974-06-15 | Фридрих Боссерт, Вульф Фатер, Курт Бауер | |
SE7812207L (en) | 1977-12-01 | 1979-06-02 | Welsh Nat School Med | APPARATUS, PROCEDURE AND MANUFACTURED PRODUCTS FOR USE IN THE ADMINISTRATION OF ANTIHISTAMINES |
ZA815698B (en) | 1980-08-28 | 1983-04-27 | Lilly Co Eli | Intranasal formulation |
DE3338978A1 (en) | 1982-10-29 | 1984-05-03 | Basf Ag, 6700 Ludwigshafen | Verapamil and gallopamil and their physiologically tolerated salts for application onto the mucous membranes of the mouth, of the naso-pharyngeal space and of the rectum for absorption |
DE3246081A1 (en) | 1982-12-13 | 1984-06-14 | G. Pohl-Boskamp GmbH & Co Chemisch-pharmazeutische Fabrik, 2214 Hohenlockstedt | Nitroglycerin spray |
US4495168A (en) * | 1983-08-22 | 1985-01-22 | Basf Wyandotte Corporation | Aerosol gel |
IT1169873B (en) | 1983-10-21 | 1987-06-03 | Prodotti Formenti Srl | PHARMACEUTICAL COMPOSITION WITH SYSTEMIC ANTI-COLINESTERASIC, AGONISTIC-COLINERGIC AND ANTI-MUSCARINIC ACTIVITY |
GB8501015D0 (en) * | 1985-01-16 | 1985-02-20 | Riker Laboratories Inc | Drug |
DE3522550A1 (en) * | 1985-06-24 | 1987-01-02 | Klinge Co Chem Pharm Fab | SPRAYABLE PHARMACEUTICAL PREPARATION FOR TOPICAL APPLICATION |
EP0213108A3 (en) | 1985-06-26 | 1987-07-15 | Kurt Dr. Burghart | Pharmaceutical preparation containing an antihypotonic as the active agent |
GB8522453D0 (en) | 1985-09-11 | 1985-10-16 | Lilly Industries Ltd | Chewable capsules |
DE3544692A1 (en) | 1985-12-18 | 1987-06-19 | Bayer Ag | DIHYDROPYRIDINE SPRAY, METHOD FOR THE PRODUCTION THEREOF AND ITS PHARMACEUTICAL USE |
US4689233A (en) | 1986-01-06 | 1987-08-25 | Siegfried Aktiengesellschaft | Coronary therapeutic agent in the form of soft gelatin capsules |
EP0259383B1 (en) * | 1986-03-10 | 1991-01-23 | Kurt Dr. Burghart | Pharmaceutical preparation and process for preparing the same |
US4863970A (en) * | 1986-11-14 | 1989-09-05 | Theratech, Inc. | Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols |
JPH0645538B2 (en) | 1987-09-30 | 1994-06-15 | 日本化薬株式会社 | Nitroglycerin spray |
DE3738236A1 (en) | 1987-11-11 | 1989-05-24 | Euro Celtique Sa | BIT CAPSULE |
US5719197A (en) * | 1988-03-04 | 1998-02-17 | Noven Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
WO1989010745A1 (en) | 1988-05-02 | 1989-11-16 | Pomerantz, Edwin | Compositions and in situ methods for forming films on body tissue |
HU199678B (en) | 1988-07-08 | 1990-03-28 | Egyt Gyogyszervegyeszeti Gyar | Process for producing aerosols containing nitroglicerol |
US5128132A (en) | 1988-11-22 | 1992-07-07 | Parnell Pharmaceuticals, Inc. | Eriodictyon compositions and methods for treating internal mucous membranes |
US5766573A (en) | 1988-12-06 | 1998-06-16 | Riker Laboratories, Inc. | Medicinal aerosol formulations |
US5225183A (en) * | 1988-12-06 | 1993-07-06 | Riker Laboratories, Inc. | Medicinal aerosol formulations |
US4935243A (en) | 1988-12-19 | 1990-06-19 | Pharmacaps, Inc. | Chewable, edible soft gelatin capsule |
US5011678A (en) | 1989-02-01 | 1991-04-30 | California Biotechnology Inc. | Composition and method for administration of pharmaceutically active substances |
DE3907414A1 (en) | 1989-03-08 | 1990-09-13 | Hoechst Ag | THE APPLICATION OF INHALED LOOP DIURETICS FOR THE TREATMENT OF ALLERGEN-INDUCED NASAL REACTIONS |
DE4000770A1 (en) | 1990-01-12 | 1991-07-18 | Reynolds Aluminium Deutschland | CONNECTION OF THE JOINT BETWEEN BAR AND POST ON A CARRIER FOR ONE OR ON A FAÇADE WALL |
DE4007705C1 (en) | 1990-03-10 | 1991-09-26 | G. Pohl-Boskamp Gmbh & Co. Chemisch-Pharmazeutische Fabrik, 2214 Hohenlockstedt, De | |
DE69122464T2 (en) * | 1990-03-30 | 1997-02-20 | Yasunori Morimoto | TRANSDERMAL ABSORBABLE AGENT WITH MORPHINE HYDROCHLORIDE |
AU7880991A (en) | 1990-05-10 | 1991-11-27 | Novo Nordisk A/S | A pharmaceutical preparation containing n-glycofurols and n-ethylene glycols |
US5370862A (en) | 1990-06-13 | 1994-12-06 | Schwarz Pharma Ag | Pharmaceutical hydrophilic spray containing nitroglycerin for treating angina |
US5143731A (en) * | 1990-08-07 | 1992-09-01 | Mediventures Incorporated | Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels |
DE4026072A1 (en) | 1990-08-17 | 1992-02-20 | Sanol Arznei Schwarz Gmbh | NITROGLYCER-CONTAINING, HYDROPHILIC, WAESSRING PUMPSPRAY |
US5166145A (en) * | 1990-09-10 | 1992-11-24 | Alza Corporation | Antiemetic therapy |
DE4038203A1 (en) | 1990-11-30 | 1992-06-04 | Kali Chemie Pharma Gmbh | Pharmaceutical spray-prepn. for admin. of nitrate(s) - esp. for treatment of cardiovascular, disorders, asthma, migraine and colic |
US5135753A (en) | 1991-03-12 | 1992-08-04 | Pharmetrix Corporation | Method and therapeutic system for smoking cessation |
EP0504112A3 (en) | 1991-03-14 | 1993-04-21 | Ciba-Geigy Ag | Pharmaceutical aerosol formulations |
DE4112303A1 (en) | 1991-04-15 | 1992-10-22 | Minnesota Mining & Mfg | Nitroglycerin, propellant gas-free spray prepn. - stored in container in which the steel parts are made of V4A series steels to inhibit nitroglycerin decomposition |
ES2181673T3 (en) * | 1991-05-01 | 2003-03-01 | Jackson H M Found Military Med | PROCESS OF TREATMENT OF INFECTIOUS RESPIRATORY DISEASES. |
DE69208660T2 (en) | 1991-06-10 | 1996-07-11 | Schering Corp | FLUORINE CHLORINE HYDROGEN-FREE AEROSOL FORMULATIONS |
GB9118830D0 (en) | 1991-09-03 | 1991-10-16 | Minnesota Mining & Mfg | Medical aerosol formulations |
DE4132176C2 (en) | 1991-09-27 | 1997-03-13 | Ig Spruehtechnik Gmbh | Metered aerosols with isobutane as propellant |
US5457100A (en) | 1991-12-02 | 1995-10-10 | Daniel; David G. | Method for treatment of recurrent paroxysmal neuropsychiatric |
US5824307A (en) * | 1991-12-23 | 1998-10-20 | Medimmune, Inc. | Human-murine chimeric antibodies against respiratory syncytial virus |
DE69305759T2 (en) | 1992-02-20 | 1997-06-12 | Johannes Louw K Von Wielligh | Product to support smoking cessation |
US5294433A (en) * | 1992-04-15 | 1994-03-15 | The Procter & Gamble Company | Use of H-2 antagonists for treatment of gingivitis |
PT679088E (en) * | 1992-09-29 | 2002-12-31 | Inhale Therapeutic Syst | PULMONARY ADMINISTRATION OF ACTIVE FRAGMENTS OF PARTIROID HORMONE |
EP0627915B1 (en) | 1992-12-04 | 1999-10-13 | Mayor Pharmaceuticals Laboratories,Inc. | Sprayable analgesic composition and method of use |
US5981591A (en) | 1992-12-04 | 1999-11-09 | Mayor Pharmaceutical Laboratories, Inc. | Sprayable analgesic composition and method of use |
ES2122261T3 (en) * | 1993-03-17 | 1998-12-16 | Minnesota Mining & Mfg | AEROSOL FORMULATION CONTAINING A DISPERSION ADJUVANT DERIVED FROM AN ESTER, AMIDA OR MERCAPTOESTER. |
US5362496A (en) | 1993-08-04 | 1994-11-08 | Pharmetrix Corporation | Method and therapeutic system for smoking cessation |
GB9401891D0 (en) * | 1994-02-01 | 1994-03-30 | Boots Co Plc | Therapeutic agents |
US5502076A (en) * | 1994-03-08 | 1996-03-26 | Hoffmann-La Roche Inc. | Dispersing agents for use with hydrofluoroalkane propellants |
GB9405304D0 (en) | 1994-03-16 | 1994-04-27 | Scherer Ltd R P | Delivery systems for hydrophobic drugs |
WO1995031182A1 (en) * | 1994-05-13 | 1995-11-23 | Aradigm Corporation | Narcotic containing aerosol formulation |
US5519059A (en) | 1994-08-17 | 1996-05-21 | Sawaya; Assad S. | Antifungal formulation |
US5456677A (en) | 1994-08-22 | 1995-10-10 | Spector; John E. | Method for oral spray administration of caffeine |
NZ280610A (en) | 1994-12-29 | 1997-08-22 | Mcneil Ppc Inc | Soft gelatin-like pharmaceutical carrier: gelled polyethylene glycol and dispersed active agent |
US5563177A (en) * | 1995-01-30 | 1996-10-08 | American Home Products Corporation | Taste masking guaifenesin containing liquids |
US5908611A (en) * | 1995-05-05 | 1999-06-01 | The Scripps Research Institute | Treatment of viscous mucous-associated diseases |
US5635161A (en) * | 1995-06-07 | 1997-06-03 | Abbott Laboratories | Aerosol drug formulations containing vegetable oils |
US6258032B1 (en) * | 1997-01-29 | 2001-07-10 | William M. Hammesfahr | Method of diagnosis and treatment and related compositions and apparatus |
AUPN814496A0 (en) * | 1996-02-19 | 1996-03-14 | Monash University | Dermal penetration enhancer |
AU2190697A (en) | 1996-04-12 | 1997-11-07 | Flemington Pharmaceutical Corporation | Buccal polar spray or capsule |
US5869082A (en) | 1996-04-12 | 1999-02-09 | Flemington Pharmaceutical Corp. | Buccal, non-polar spray for nitroglycerin |
US5955098A (en) | 1996-04-12 | 1999-09-21 | Flemington Pharmaceutical Corp. | Buccal non polar spray or capsule |
US6271240B1 (en) * | 1996-05-06 | 2001-08-07 | David Lew Simon | Methods for improved regulation of endogenous dopamine in prolonged treatment of opioid addicted individuals |
US5891465A (en) * | 1996-05-14 | 1999-04-06 | Biozone Laboratories, Inc. | Delivery of biologically active material in a liposomal formulation for administration into the mouth |
US5795909A (en) * | 1996-05-22 | 1998-08-18 | Neuromedica, Inc. | DHA-pharmaceutical agent conjugates of taxanes |
US5976573A (en) * | 1996-07-03 | 1999-11-02 | Rorer Pharmaceutical Products Inc. | Aqueous-based pharmaceutical composition |
US6071539A (en) | 1996-09-20 | 2000-06-06 | Ethypharm, Sa | Effervescent granules and methods for their preparation |
ZA9711732B (en) | 1996-12-31 | 1998-12-28 | Quadrant Holdings Cambridge | Methods and compositions for improvement bioavailability of bioactive agents for mucosal delivery |
US5906811A (en) * | 1997-06-27 | 1999-05-25 | Thione International, Inc. | Intra-oral antioxidant preparations |
US20050180923A1 (en) * | 1997-10-01 | 2005-08-18 | Dugger Harry A.Iii | Buccal, polar and non-polar spray containing testosterone |
US20040136915A1 (en) * | 1997-10-01 | 2004-07-15 | Dugger Harry A. | Buccal, polar and non-polar spray containing atropine |
US20040141923A1 (en) * | 1997-10-01 | 2004-07-22 | Dugger Harry A. | Buccal, polar and non-polar spray containing alprazolam |
US7632517B2 (en) * | 1997-10-01 | 2009-12-15 | Novadel Pharma Inc. | Buccal, polar and non-polar spray containing zolpidem |
US20050281752A1 (en) * | 1997-10-01 | 2005-12-22 | Dugger Harry A Iii | Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system |
US20030095927A1 (en) * | 1997-10-01 | 2003-05-22 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating muscular and skeletal disorders |
US20030095926A1 (en) * | 1997-10-01 | 2003-05-22 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract |
US20040136914A1 (en) * | 1997-10-01 | 2004-07-15 | Dugger Harry A. | Buccal, polar and non-polar spray containing ondansetron |
US20030077229A1 (en) * | 1997-10-01 | 2003-04-24 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs |
EP1029536B1 (en) * | 1997-10-01 | 2007-11-28 | Novadel Pharma Inc. | Buccal non-polar spray |
US20050163719A1 (en) * | 1997-10-01 | 2005-07-28 | Dugger Harry A.Iii | Buccal, polar and non-polar spray containing diazepam |
US20030095925A1 (en) * | 1997-10-01 | 2003-05-22 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders |
US20030077227A1 (en) * | 1997-10-01 | 2003-04-24 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system |
US20030077228A1 (en) * | 1997-10-01 | 2003-04-24 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating endocrine disorders |
US20050287075A1 (en) * | 1997-10-01 | 2005-12-29 | Dugger Harry A Iii | Buccal, polar and non-polar spray or capsule containing drugs for treating pain |
US20030185761A1 (en) * | 1997-10-01 | 2003-10-02 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating pain |
US20030082107A1 (en) * | 1997-10-01 | 2003-05-01 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating an infectious disease or cancer |
US20090162300A1 (en) * | 1997-10-01 | 2009-06-25 | Dugger Iii Harry A | Buccal, polar and non-polar spray containing alprazolam |
US20050002867A1 (en) * | 1997-10-01 | 2005-01-06 | Novadel Pharma Inc. | Buccal, polar and non-polar sprays containing propofol |
US20030190286A1 (en) * | 1997-10-01 | 2003-10-09 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating allergies or asthma |
US20040136913A1 (en) * | 1997-10-01 | 2004-07-15 | Dugger Harry A. | Buccal, polar and non-polar spray containing sumatriptan |
US6212227B1 (en) * | 1997-12-02 | 2001-04-03 | Conexant Systems, Inc. | Constant envelope modulation for splitterless DSL transmission |
CN100358494C (en) | 1998-11-12 | 2008-01-02 | 弗兰克G·皮尔基威克兹 | Inhalation system |
US6375975B1 (en) * | 1998-12-21 | 2002-04-23 | Generex Pharmaceuticals Incorporated | Pharmaceutical compositions for buccal and pulmonary application |
GB9908921D0 (en) * | 1999-04-19 | 1999-06-16 | Britannia Pharmaceuticals Ltd | Spray dispenser for opiod antagonists |
JP3127918B1 (en) * | 1999-07-14 | 2001-01-29 | 住友電気工業株式会社 | Road-to-vehicle communication system, roadside communication station and on-vehicle mobile station |
CO5271697A1 (en) * | 2000-01-12 | 2003-04-30 | Pfizer Prod Inc | COMPOSITIONS AND PROCEDURES FOR THE TREATMENT OF AFFECTIONS THAT RESPOND TO AN INCREASE OF TESTOSTERONE |
CZ303537B6 (en) * | 2000-03-09 | 2012-11-21 | Gw Pharma Limited | Use of cannabis for preparing pharmaceutical formulation and pump spray device |
AU4866001A (en) * | 2000-03-28 | 2001-10-08 | Farmarc Nederland Bv | Alprazolam inclusion complexes and pharmaceutical compositions thereof |
EP1343521A2 (en) * | 2000-12-01 | 2003-09-17 | Battelle Memorial Institute | Method for the stabilizing biomolecules (e.g. insulin) in liquid formulations |
DE60231611D1 (en) * | 2001-05-24 | 2009-04-30 | Alexza Pharmaceuticals Inc | ADMINISTRATION OF OPIOIDES BY INHALATION |
WO2002094232A1 (en) | 2001-05-24 | 2002-11-28 | Alexza Molecular Delivery Corporation | Delivery of antidepressants through an inhalation route |
-
2002
- 2002-08-29 US US10/230,059 patent/US20030185761A1/en not_active Abandoned
-
2003
- 2003-08-27 JP JP2004551444A patent/JP2006505611A/en active Pending
- 2003-08-27 CA CA002497268A patent/CA2497268A1/en not_active Abandoned
- 2003-08-27 NZ NZ539284A patent/NZ539284A/en not_active IP Right Cessation
- 2003-08-27 WO PCT/US2003/026859 patent/WO2004043428A2/en active Application Filing
- 2003-08-27 AU AU2003296899A patent/AU2003296899A1/en not_active Abandoned
- 2003-08-27 EP EP03811212A patent/EP1539107A2/en not_active Withdrawn
- 2003-12-04 US US10/726,625 patent/US6969508B2/en not_active Expired - Fee Related
-
2009
- 2009-01-09 US US12/351,606 patent/US20090124554A1/en not_active Abandoned
-
2012
- 2012-05-09 US US13/467,441 patent/US20120252846A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2006505611A (en) | 2006-02-16 |
WO2004043428A2 (en) | 2004-05-27 |
WO2004043428A3 (en) | 2004-10-21 |
US20040120896A1 (en) | 2004-06-24 |
EP1539107A2 (en) | 2005-06-15 |
AU2003296899A1 (en) | 2004-06-03 |
US6969508B2 (en) | 2005-11-29 |
US20030185761A1 (en) | 2003-10-02 |
US20120252846A1 (en) | 2012-10-04 |
NZ539284A (en) | 2007-07-27 |
US20090124554A1 (en) | 2009-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6969508B2 (en) | Buccal, polar and non-polar spray or capsule containing drugs for treating pain | |
US20060165604A1 (en) | Buccal, polar and non-polar spray containing sumatriptan | |
US6998110B2 (en) | Buccal, polar and non-polar spray or capsule | |
US20030095927A1 (en) | Buccal, polar and non-polar spray or capsule containing drugs for treating muscular and skeletal disorders | |
US20120202866A1 (en) | Buccal, polar and non-polar spray containing ondansetron | |
US20030095925A1 (en) | Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders | |
US20050287075A1 (en) | Buccal, polar and non-polar spray or capsule containing drugs for treating pain | |
EP1539097A1 (en) | Buccal, polar and non-polar spray or capsule containing drugs for treating allergies or asthma | |
WO2004019911A2 (en) | Buccal, polar or non-polar spray or capsule containing drugs for treating endocrine disorders | |
EP1444976A1 (en) | Buccal, polar and non-polar spray or capsule |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |